<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
    <id>https://macwaneric.github.io/cancer.rss.feed/index.html</id>
    <title>CancerFeed</title>
    <updated>2023-06-27T01:12:40.495Z</updated>
    <generator>osmosfeed 1.15.1</generator>
    <link rel="alternate" href="https://macwaneric.github.io/cancer.rss.feed/index.html"/>
    <link rel="self" href="https://macwaneric.github.io/cancer.rss.feed/feed.atom"/>
    <entry>
        <title type="html"><![CDATA[Myeloproliferative neoplasms - blurring the lines between cancer and chronic inflammatory disorder]]></title>
        <id>pubmed:37361587</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37361587/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative Neoplasm (MPN) is a group of chronic blood cancers that arise from a hematopoietic stem cell (HSC) clone with somatic mutations causing constitutive activation of myeloid cytokine receptor signaling. In addition to elevated blood cell counts, MPN typically presents with increased inflammatory signaling and inflammation symptoms. Therefore, while being a clonally derived neoplasm, MPN has much in common with chronic non-cancerous inflammatory conditions, such as rheumatoid...]]></summary>
        <author>
            <name>Eli M Soyfer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomics of <em>ERBB2</em>-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab]]></title>
        <id>pubmed:37364233</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37364233/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: ERBB2-positive BCs in young women displayed substantial genomic evolution after treatment with chemo + H. Approximately half of patients with paired samples demonstrated acquired and/or clonally enriched genomic changes in cancer genes. ERBB2 CN changes were uncommon. We identified several genes warranting exploration as potential mechanisms of resistance to therapy in this population.]]></summary>
        <author>
            <name>Marla Lipsyc-Sharf</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen-receptor pathway inhibitors]]></title>
        <id>pubmed:37364000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37364000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Low AR activity, activation of stemness programs, and Hedgehog pathway were associated with primary ARPIs' resistance, whereas most acquired resistance was associated with subclonal evolution, AR-related events, and neuroendocrine differentiation.]]></summary>
        <author>
            <name>Naoual Menssouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Research Progress on Gene Mutation and CHIP in Pathogenesis of MDS --Review]]></title>
        <id>pubmed:37356959</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37356959/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With the development of molecular biology techniques, the people's understanding of myelodysplastic syndromes (MDS) has greatly improved, a heterogeneous hematopoietic pre-malignant disorder of the stem cells. Gene mutations include RNA splicing, DNA methylation, chromosome modification, transcription factors, signal transduction kinases, RAS pathways, cohesion complexes, DNA repair, etc. Gene mutation is the determinant of diagnostic typing and therapeutic efficacy of MDS. The new concepts of...]]></summary>
        <author>
            <name>Miao He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery?]]></title>
        <id>pubmed:37356012</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37356012/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution to secondary paroxysmal nocturnal hemoglobinuria (PNH) or myeloid neoplasia (MN) represents one of the long-term complications of patients with aplastic anemia (AA). The recent evidence in the field of immunology and the application of next-generation sequencing have shed light on the molecular underpinnings of these clonal complications, revealing clinical and molecular risk factors as well as potential immunological players. Particularly, whether MN evolution represents a...]]></summary>
        <author>
            <name>Carmelo Gurnari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery?]]></title>
        <id>pubmed:37356012</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37356012/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution to secondary paroxysmal nocturnal hemoglobinuria (PNH) or myeloid neoplasia (MN) represents one of the long-term complications of patients with aplastic anemia (AA). The recent evidence in the field of immunology and the application of next-generation sequencing have shed light on the molecular underpinnings of these clonal complications, revealing clinical and molecular risk factors as well as potential immunological players. Particularly, whether MN evolution represents a...]]></summary>
        <author>
            <name>Carmelo Gurnari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery?]]></title>
        <id>pubmed:37356012</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37356012/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution to secondary paroxysmal nocturnal hemoglobinuria (PNH) or myeloid neoplasia (MN) represents one of the long-term complications of patients with aplastic anemia (AA). The recent evidence in the field of immunology and the application of next-generation sequencing have shed light on the molecular underpinnings of these clonal complications, revealing clinical and molecular risk factors as well as potential immunological players. Particularly, whether MN evolution represents a...]]></summary>
        <author>
            <name>Carmelo Gurnari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery?]]></title>
        <id>pubmed:37356012</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37356012/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution to secondary paroxysmal nocturnal hemoglobinuria (PNH) or myeloid neoplasia (MN) represents one of the long-term complications of patients with aplastic anemia (AA). The recent evidence in the field of immunology and the application of next-generation sequencing have shed light on the molecular underpinnings of these clonal complications, revealing clinical and molecular risk factors as well as potential immunological players. Particularly, whether MN evolution represents a...]]></summary>
        <author>
            <name>Carmelo Gurnari</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Vitro and In Vivo Models for Metastatic Intestinal Tumors Using Genotype-Defined Organoids]]></title>
        <id>pubmed:37355534</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37355534/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[It has been established that the accumulation of driver gene mutations causes malignant progression of colorectal cancer (CRC) through positive selection and clonal expansion, similar to Darwin's evolution. Following this multistep tumorigenesis concept, we previously showed the specific mutation patterns for each process of malignant progression, including submucosal invasion, epithelial mesenchymal transition (EMT), intravasation, and metastasis, using genetically engineered mouse and organoid...]]></summary>
        <author>
            <name>Atsuya Morita</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[In Vitro and In Vivo Models for Metastatic Intestinal Tumors Using Genotype-Defined Organoids]]></title>
        <id>pubmed:37355534</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37355534/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[It has been established that the accumulation of driver gene mutations causes malignant progression of colorectal cancer (CRC) through positive selection and clonal expansion, similar to Darwin's evolution. Following this multistep tumorigenesis concept, we previously showed the specific mutation patterns for each process of malignant progression, including submucosal invasion, epithelial mesenchymal transition (EMT), intravasation, and metastasis, using genetically engineered mouse and organoid...]]></summary>
        <author>
            <name>Atsuya Morita</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA]]></title>
        <id>pubmed:37349125</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37349125/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies using cell-free circulating tumor DNA (ctDNA) are being used frequently in both research and clinical settings. ctDNA can be used to identify actionable mutations to personalize systemic therapy, detect post-treatment minimal residual disease (MRD), and predict responses to immunotherapy. ctDNA can also be isolated from a range of different biofluids, with the possibility of detecting locoregional MRD with increased sensitivity if sampling more proximally than blood plasma....]]></summary>
        <author>
            <name>Nicholas P Semenkovich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Birth Weight Is Associated With Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Outcomes in Adulthood]]></title>
        <id>pubmed:37345823</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37345823/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Background High and low birth weight are independently associated with increased cardiovascular disease risk in adulthood. Clonal hematopoiesis of indeterminate potential (CHIP), the age-related clonal expansion of hematopoietic cells with preleukemic somatic mutations, predicts incident cardiovascular disease independent of traditional cardiovascular risk factors. Whether birth weight predicts development of CHIP later in life is unknown. Methods and Results A total of 221 047 adults enrolled...]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA]]></title>
        <id>pubmed:37349125</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37349125/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies using cell-free circulating tumor DNA (ctDNA) are being used frequently in both research and clinical settings. ctDNA can be used to identify actionable mutations to personalize systemic therapy, detect post-treatment minimal residual disease (MRD), and predict responses to immunotherapy. ctDNA can also be isolated from a range of different biofluids, with the possibility of detecting locoregional MRD with increased sensitivity if sampling more proximally than blood plasma....]]></summary>
        <author>
            <name>Nicholas P Semenkovich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Birth Weight Is Associated With Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Outcomes in Adulthood]]></title>
        <id>pubmed:37345823</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37345823/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Background High and low birth weight are independently associated with increased cardiovascular disease risk in adulthood. Clonal hematopoiesis of indeterminate potential (CHIP), the age-related clonal expansion of hematopoietic cells with preleukemic somatic mutations, predicts incident cardiovascular disease independent of traditional cardiovascular risk factors. Whether birth weight predicts development of CHIP later in life is unknown. Methods and Results A total of 221 047 adults enrolled...]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA]]></title>
        <id>pubmed:37349125</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37349125/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies using cell-free circulating tumor DNA (ctDNA) are being used frequently in both research and clinical settings. ctDNA can be used to identify actionable mutations to personalize systemic therapy, detect post-treatment minimal residual disease (MRD), and predict responses to immunotherapy. ctDNA can also be isolated from a range of different biofluids, with the possibility of detecting locoregional MRD with increased sensitivity if sampling more proximally than blood plasma....]]></summary>
        <author>
            <name>Nicholas P Semenkovich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Birth Weight Is Associated With Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Outcomes in Adulthood]]></title>
        <id>pubmed:37345823</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37345823/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Background High and low birth weight are independently associated with increased cardiovascular disease risk in adulthood. Clonal hematopoiesis of indeterminate potential (CHIP), the age-related clonal expansion of hematopoietic cells with preleukemic somatic mutations, predicts incident cardiovascular disease independent of traditional cardiovascular risk factors. Whether birth weight predicts development of CHIP later in life is unknown. Methods and Results A total of 221 047 adults enrolled...]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA]]></title>
        <id>pubmed:37349125</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37349125/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Liquid biopsies using cell-free circulating tumor DNA (ctDNA) are being used frequently in both research and clinical settings. ctDNA can be used to identify actionable mutations to personalize systemic therapy, detect post-treatment minimal residual disease (MRD), and predict responses to immunotherapy. ctDNA can also be isolated from a range of different biofluids, with the possibility of detecting locoregional MRD with increased sensitivity if sampling more proximally than blood plasma....]]></summary>
        <author>
            <name>Nicholas P Semenkovich</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Birth Weight Is Associated With Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Outcomes in Adulthood]]></title>
        <id>pubmed:37345823</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37345823/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Background High and low birth weight are independently associated with increased cardiovascular disease risk in adulthood. Clonal hematopoiesis of indeterminate potential (CHIP), the age-related clonal expansion of hematopoietic cells with preleukemic somatic mutations, predicts incident cardiovascular disease independent of traditional cardiovascular risk factors. Whether birth weight predicts development of CHIP later in life is unknown. Methods and Results A total of 221 047 adults enrolled...]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Birth Weight Is Associated With Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Outcomes in Adulthood]]></title>
        <id>pubmed:37345823</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37345823/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Background High and low birth weight are independently associated with increased cardiovascular disease risk in adulthood. Clonal hematopoiesis of indeterminate potential (CHIP), the age-related clonal expansion of hematopoietic cells with preleukemic somatic mutations, predicts incident cardiovascular disease independent of traditional cardiovascular risk factors. Whether birth weight predicts development of CHIP later in life is unknown. Methods and Results A total of 221 047 adults enrolled...]]></summary>
        <author>
            <name>Art Schuermans</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bilateral Adrenal Infarction that Developed in Latent Essential Thrombocythemia]]></title>
        <id>pubmed:37344430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37344430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bilateral adrenal infarction is an extremely rare disease, and it has been reported that some coagulation abnormalities, including essential thrombocythemia (ET), exist in the background. We herein report a 76-year-old patient in whom the platelet count had been in the normal range at the onset of adrenal infarction but subsequently increased to 102×10⁴/μL at 7 months later, leading to the diagnosis of JAK2V617F-positive ET. As the presence of the JAK2V617F mutation increases the risk of...]]></summary>
        <author>
            <name>Yurika Hada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface]]></title>
        <id>pubmed:37343201</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37343201/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent larger-scale studies of patients with cancer and longitudinal population cohorts have revealed how age-related expansions of mutant hematopoietic cells (clonal hematopoiesis [CH]) have differential associations with incident and prevalent cancers and their outcomes. Increasing recognition and deeper understanding of genetic subtypes of CH are yielding insights into the tumor-immune interface that may help to explain the heterogeneous impact of CH on tumorigenesis and treatment. Herein, we...]]></summary>
        <author>
            <name>Marco M Buttigieg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bilateral Adrenal Infarction that Developed in Latent Essential Thrombocythemia]]></title>
        <id>pubmed:37344430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37344430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bilateral adrenal infarction is an extremely rare disease, and it has been reported that some coagulation abnormalities, including essential thrombocythemia (ET), exist in the background. We herein report a 76-year-old patient in whom the platelet count had been in the normal range at the onset of adrenal infarction but subsequently increased to 102×10⁴/μL at 7 months later, leading to the diagnosis of JAK2V617F-positive ET. As the presence of the JAK2V617F mutation increases the risk of...]]></summary>
        <author>
            <name>Yurika Hada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface]]></title>
        <id>pubmed:37343201</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37343201/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent larger-scale studies of patients with cancer and longitudinal population cohorts have revealed how age-related expansions of mutant hematopoietic cells (clonal hematopoiesis [CH]) have differential associations with incident and prevalent cancers and their outcomes. Increasing recognition and deeper understanding of genetic subtypes of CH are yielding insights into the tumor-immune interface that may help to explain the heterogeneous impact of CH on tumorigenesis and treatment. Herein, we...]]></summary>
        <author>
            <name>Marco M Buttigieg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bilateral Adrenal Infarction that Developed in Latent Essential Thrombocythemia]]></title>
        <id>pubmed:37344430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37344430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bilateral adrenal infarction is an extremely rare disease, and it has been reported that some coagulation abnormalities, including essential thrombocythemia (ET), exist in the background. We herein report a 76-year-old patient in whom the platelet count had been in the normal range at the onset of adrenal infarction but subsequently increased to 102×10⁴/μL at 7 months later, leading to the diagnosis of JAK2V617F-positive ET. As the presence of the JAK2V617F mutation increases the risk of...]]></summary>
        <author>
            <name>Yurika Hada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface]]></title>
        <id>pubmed:37343201</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37343201/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent larger-scale studies of patients with cancer and longitudinal population cohorts have revealed how age-related expansions of mutant hematopoietic cells (clonal hematopoiesis [CH]) have differential associations with incident and prevalent cancers and their outcomes. Increasing recognition and deeper understanding of genetic subtypes of CH are yielding insights into the tumor-immune interface that may help to explain the heterogeneous impact of CH on tumorigenesis and treatment. Herein, we...]]></summary>
        <author>
            <name>Marco M Buttigieg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bilateral Adrenal Infarction that Developed in Latent Essential Thrombocythemia]]></title>
        <id>pubmed:37344430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37344430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bilateral adrenal infarction is an extremely rare disease, and it has been reported that some coagulation abnormalities, including essential thrombocythemia (ET), exist in the background. We herein report a 76-year-old patient in whom the platelet count had been in the normal range at the onset of adrenal infarction but subsequently increased to 102×10⁴/μL at 7 months later, leading to the diagnosis of JAK2V617F-positive ET. As the presence of the JAK2V617F mutation increases the risk of...]]></summary>
        <author>
            <name>Yurika Hada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface]]></title>
        <id>pubmed:37343201</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37343201/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent larger-scale studies of patients with cancer and longitudinal population cohorts have revealed how age-related expansions of mutant hematopoietic cells (clonal hematopoiesis [CH]) have differential associations with incident and prevalent cancers and their outcomes. Increasing recognition and deeper understanding of genetic subtypes of CH are yielding insights into the tumor-immune interface that may help to explain the heterogeneous impact of CH on tumorigenesis and treatment. Herein, we...]]></summary>
        <author>
            <name>Marco M Buttigieg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bilateral Adrenal Infarction that Developed in Latent Essential Thrombocythemia]]></title>
        <id>pubmed:37344430</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37344430/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bilateral adrenal infarction is an extremely rare disease, and it has been reported that some coagulation abnormalities, including essential thrombocythemia (ET), exist in the background. We herein report a 76-year-old patient in whom the platelet count had been in the normal range at the onset of adrenal infarction but subsequently increased to 102×10⁴/μL at 7 months later, leading to the diagnosis of JAK2V617F-positive ET. As the presence of the JAK2V617F mutation increases the risk of...]]></summary>
        <author>
            <name>Yurika Hada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface]]></title>
        <id>pubmed:37343201</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37343201/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent larger-scale studies of patients with cancer and longitudinal population cohorts have revealed how age-related expansions of mutant hematopoietic cells (clonal hematopoiesis [CH]) have differential associations with incident and prevalent cancers and their outcomes. Increasing recognition and deeper understanding of genetic subtypes of CH are yielding insights into the tumor-immune interface that may help to explain the heterogeneous impact of CH on tumorigenesis and treatment. Herein, we...]]></summary>
        <author>
            <name>Marco M Buttigieg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface]]></title>
        <id>pubmed:37343201</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37343201/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent larger-scale studies of patients with cancer and longitudinal population cohorts have revealed how age-related expansions of mutant hematopoietic cells (clonal hematopoiesis [CH]) have differential associations with incident and prevalent cancers and their outcomes. Increasing recognition and deeper understanding of genetic subtypes of CH are yielding insights into the tumor-immune interface that may help to explain the heterogeneous impact of CH on tumorigenesis and treatment. Herein, we...]]></summary>
        <author>
            <name>Marco M Buttigieg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling and predicting cancer clonal evolution with reinforcement learning]]></title>
        <id>pubmed:37344104</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37344104/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer results from an evolutionary process that typically yields multiple clones with varying sets of mutations within the same tumor. Accurately modeling this process is key to understanding and predicting cancer evolution. Here, we introduce CloMu (Clone To Mutation), a flexible and low-parameter tree-generative model of cancer evolution. CloMu uses a two-layer neural network trained via reinforcement learning to determine the probability of new mutations based on the existing mutations on a...]]></summary>
        <author>
            <name>Stefan Ivanovic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface]]></title>
        <id>pubmed:37343201</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37343201/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent larger-scale studies of patients with cancer and longitudinal population cohorts have revealed how age-related expansions of mutant hematopoietic cells (clonal hematopoiesis [CH]) have differential associations with incident and prevalent cancers and their outcomes. Increasing recognition and deeper understanding of genetic subtypes of CH are yielding insights into the tumor-immune interface that may help to explain the heterogeneous impact of CH on tumorigenesis and treatment. Herein, we...]]></summary>
        <author>
            <name>Marco M Buttigieg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phenotyping of lymphoproliferative tumours generated in xenografts of non-small cell lung cancer]]></title>
        <id>pubmed:37342197</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37342197/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Patient-derived xenograft (PDX) models involve the engraftment of tumour tissue in immunocompromised mice and represent an important pre-clinical oncology research method. A limitation of non-small cell lung cancer (NSCLC) PDX model derivation in NOD-scid IL2Rgamma^(null) (NSG) mice is that a subset of initial engraftments are of lymphocytic, rather than tumour origin.]]></summary>
        <author>
            <name>David R Pearce</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling and predicting cancer clonal evolution with reinforcement learning]]></title>
        <id>pubmed:37344104</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37344104/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer results from an evolutionary process that typically yields multiple clones with varying sets of mutations within the same tumor. Accurately modeling this process is key to understanding and predicting cancer evolution. Here, we introduce CloMu (Clone To Mutation), a flexible and low-parameter tree-generative model of cancer evolution. CloMu uses a two-layer neural network trained via reinforcement learning to determine the probability of new mutations based on the existing mutations on a...]]></summary>
        <author>
            <name>Stefan Ivanovic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface]]></title>
        <id>pubmed:37343201</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37343201/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent larger-scale studies of patients with cancer and longitudinal population cohorts have revealed how age-related expansions of mutant hematopoietic cells (clonal hematopoiesis [CH]) have differential associations with incident and prevalent cancers and their outcomes. Increasing recognition and deeper understanding of genetic subtypes of CH are yielding insights into the tumor-immune interface that may help to explain the heterogeneous impact of CH on tumorigenesis and treatment. Herein, we...]]></summary>
        <author>
            <name>Marco M Buttigieg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phenotyping of lymphoproliferative tumours generated in xenografts of non-small cell lung cancer]]></title>
        <id>pubmed:37342197</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37342197/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Patient-derived xenograft (PDX) models involve the engraftment of tumour tissue in immunocompromised mice and represent an important pre-clinical oncology research method. A limitation of non-small cell lung cancer (NSCLC) PDX model derivation in NOD-scid IL2Rgamma^(null) (NSG) mice is that a subset of initial engraftments are of lymphocytic, rather than tumour origin.]]></summary>
        <author>
            <name>David R Pearce</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling and predicting cancer clonal evolution with reinforcement learning]]></title>
        <id>pubmed:37344104</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37344104/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer results from an evolutionary process that typically yields multiple clones with varying sets of mutations within the same tumor. Accurately modeling this process is key to understanding and predicting cancer evolution. Here, we introduce CloMu (Clone To Mutation), a flexible and low-parameter tree-generative model of cancer evolution. CloMu uses a two-layer neural network trained via reinforcement learning to determine the probability of new mutations based on the existing mutations on a...]]></summary>
        <author>
            <name>Stefan Ivanovic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface]]></title>
        <id>pubmed:37343201</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37343201/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent larger-scale studies of patients with cancer and longitudinal population cohorts have revealed how age-related expansions of mutant hematopoietic cells (clonal hematopoiesis [CH]) have differential associations with incident and prevalent cancers and their outcomes. Increasing recognition and deeper understanding of genetic subtypes of CH are yielding insights into the tumor-immune interface that may help to explain the heterogeneous impact of CH on tumorigenesis and treatment. Herein, we...]]></summary>
        <author>
            <name>Marco M Buttigieg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phenotyping of lymphoproliferative tumours generated in xenografts of non-small cell lung cancer]]></title>
        <id>pubmed:37342197</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37342197/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Patient-derived xenograft (PDX) models involve the engraftment of tumour tissue in immunocompromised mice and represent an important pre-clinical oncology research method. A limitation of non-small cell lung cancer (NSCLC) PDX model derivation in NOD-scid IL2Rgamma^(null) (NSG) mice is that a subset of initial engraftments are of lymphocytic, rather than tumour origin.]]></summary>
        <author>
            <name>David R Pearce</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling and predicting cancer clonal evolution with reinforcement learning]]></title>
        <id>pubmed:37344104</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37344104/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer results from an evolutionary process that typically yields multiple clones with varying sets of mutations within the same tumor. Accurately modeling this process is key to understanding and predicting cancer evolution. Here, we introduce CloMu (Clone To Mutation), a flexible and low-parameter tree-generative model of cancer evolution. CloMu uses a two-layer neural network trained via reinforcement learning to determine the probability of new mutations based on the existing mutations on a...]]></summary>
        <author>
            <name>Stefan Ivanovic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis: Updates and Implications at the Solid Tumor-Immune Interface]]></title>
        <id>pubmed:37343201</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37343201/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent larger-scale studies of patients with cancer and longitudinal population cohorts have revealed how age-related expansions of mutant hematopoietic cells (clonal hematopoiesis [CH]) have differential associations with incident and prevalent cancers and their outcomes. Increasing recognition and deeper understanding of genetic subtypes of CH are yielding insights into the tumor-immune interface that may help to explain the heterogeneous impact of CH on tumorigenesis and treatment. Herein, we...]]></summary>
        <author>
            <name>Marco M Buttigieg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phenotyping of lymphoproliferative tumours generated in xenografts of non-small cell lung cancer]]></title>
        <id>pubmed:37342197</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37342197/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Patient-derived xenograft (PDX) models involve the engraftment of tumour tissue in immunocompromised mice and represent an important pre-clinical oncology research method. A limitation of non-small cell lung cancer (NSCLC) PDX model derivation in NOD-scid IL2Rgamma^(null) (NSG) mice is that a subset of initial engraftments are of lymphocytic, rather than tumour origin.]]></summary>
        <author>
            <name>David R Pearce</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Modeling and predicting cancer clonal evolution with reinforcement learning]]></title>
        <id>pubmed:37344104</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37344104/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer results from an evolutionary process that typically yields multiple clones with varying sets of mutations within the same tumor. Accurately modeling this process is key to understanding and predicting cancer evolution. Here, we introduce CloMu (Clone To Mutation), a flexible and low-parameter tree-generative model of cancer evolution. CloMu uses a two-layer neural network trained via reinforcement learning to determine the probability of new mutations based on the existing mutations on a...]]></summary>
        <author>
            <name>Stefan Ivanovic</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phenotyping of lymphoproliferative tumours generated in xenografts of non-small cell lung cancer]]></title>
        <id>pubmed:37342197</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37342197/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Patient-derived xenograft (PDX) models involve the engraftment of tumour tissue in immunocompromised mice and represent an important pre-clinical oncology research method. A limitation of non-small cell lung cancer (NSCLC) PDX model derivation in NOD-scid IL2Rgamma^(null) (NSG) mice is that a subset of initial engraftments are of lymphocytic, rather than tumour origin.]]></summary>
        <author>
            <name>David R Pearce</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phenotyping of lymphoproliferative tumours generated in xenografts of non-small cell lung cancer]]></title>
        <id>pubmed:37342197</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37342197/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Patient-derived xenograft (PDX) models involve the engraftment of tumour tissue in immunocompromised mice and represent an important pre-clinical oncology research method. A limitation of non-small cell lung cancer (NSCLC) PDX model derivation in NOD-scid IL2Rgamma^(null) (NSG) mice is that a subset of initial engraftments are of lymphocytic, rather than tumour origin.]]></summary>
        <author>
            <name>David R Pearce</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic remodelling by neoadjuvant chemoradiotherapy (nCRT) and indicative role of acquired INDEL percentage for nCRT efficacy in esophageal squamous cell carcinoma]]></title>
        <id>pubmed:37339686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37339686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: nCRT remodels the genome and transcriptome of ESCC. Acquired INDEL% is a potential biomarker to indicate the effectiveness of nCRT and radiation sensitivity.]]></summary>
        <author>
            <name>Yang Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic remodelling by neoadjuvant chemoradiotherapy (nCRT) and indicative role of acquired INDEL percentage for nCRT efficacy in esophageal squamous cell carcinoma]]></title>
        <id>pubmed:37339686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37339686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: nCRT remodels the genome and transcriptome of ESCC. Acquired INDEL% is a potential biomarker to indicate the effectiveness of nCRT and radiation sensitivity.]]></summary>
        <author>
            <name>Yang Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic remodelling by neoadjuvant chemoradiotherapy (nCRT) and indicative role of acquired INDEL percentage for nCRT efficacy in esophageal squamous cell carcinoma]]></title>
        <id>pubmed:37339686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37339686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: nCRT remodels the genome and transcriptome of ESCC. Acquired INDEL% is a potential biomarker to indicate the effectiveness of nCRT and radiation sensitivity.]]></summary>
        <author>
            <name>Yang Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic remodelling by neoadjuvant chemoradiotherapy (nCRT) and indicative role of acquired INDEL percentage for nCRT efficacy in esophageal squamous cell carcinoma]]></title>
        <id>pubmed:37339686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37339686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: nCRT remodels the genome and transcriptome of ESCC. Acquired INDEL% is a potential biomarker to indicate the effectiveness of nCRT and radiation sensitivity.]]></summary>
        <author>
            <name>Yang Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic remodelling by neoadjuvant chemoradiotherapy (nCRT) and indicative role of acquired INDEL percentage for nCRT efficacy in esophageal squamous cell carcinoma]]></title>
        <id>pubmed:37339686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37339686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: nCRT remodels the genome and transcriptome of ESCC. Acquired INDEL% is a potential biomarker to indicate the effectiveness of nCRT and radiation sensitivity.]]></summary>
        <author>
            <name>Yang Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic remodelling by neoadjuvant chemoradiotherapy (nCRT) and indicative role of acquired INDEL percentage for nCRT efficacy in esophageal squamous cell carcinoma]]></title>
        <id>pubmed:37339686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37339686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: nCRT remodels the genome and transcriptome of ESCC. Acquired INDEL% is a potential biomarker to indicate the effectiveness of nCRT and radiation sensitivity.]]></summary>
        <author>
            <name>Yang Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Incident Heart Failure with Preserved Ejection Fraction]]></title>
        <id>pubmed:37333361</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37333361/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP, particularly mutations in TET2 , represents a potential new risk factor for incident HFpEF.]]></summary>
        <author>
            <name>Alex P Reiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Incident Heart Failure with Preserved Ejection Fraction]]></title>
        <id>pubmed:37333361</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37333361/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP, particularly mutations in TET2 , represents a potential new risk factor for incident HFpEF.]]></summary>
        <author>
            <name>Alex P Reiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Incident Heart Failure with Preserved Ejection Fraction]]></title>
        <id>pubmed:37333361</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37333361/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP, particularly mutations in TET2 , represents a potential new risk factor for incident HFpEF.]]></summary>
        <author>
            <name>Alex P Reiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Incident Heart Failure with Preserved Ejection Fraction]]></title>
        <id>pubmed:37333361</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37333361/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP, particularly mutations in TET2 , represents a potential new risk factor for incident HFpEF.]]></summary>
        <author>
            <name>Alex P Reiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Incident Heart Failure with Preserved Ejection Fraction]]></title>
        <id>pubmed:37333361</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37333361/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP, particularly mutations in TET2 , represents a potential new risk factor for incident HFpEF.]]></summary>
        <author>
            <name>Alex P Reiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Incident Heart Failure with Preserved Ejection Fraction]]></title>
        <id>pubmed:37333361</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37333361/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP, particularly mutations in TET2 , represents a potential new risk factor for incident HFpEF.]]></summary>
        <author>
            <name>Alex P Reiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Incident Heart Failure with Preserved Ejection Fraction]]></title>
        <id>pubmed:37333361</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37333361/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP, particularly mutations in TET2 , represents a potential new risk factor for incident HFpEF.]]></summary>
        <author>
            <name>Alex P Reiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association of Clonal Hematopoiesis of Indeterminate Potential with Incident Heart Failure with Preserved Ejection Fraction]]></title>
        <id>pubmed:37333361</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37333361/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: CHIP, particularly mutations in TET2 , represents a potential new risk factor for incident HFpEF.]]></summary>
        <author>
            <name>Alex P Reiner</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding: From developmental tracing to anti-tumor drug discovery]]></title>
        <id>pubmed:37336285</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37336285/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution has gained immense attention in explaining cancer cell status, history, and fate during cancer progression. Current single-cell or spatial transcriptome technologies have broadened our understanding of various mechanisms underlying cancer initiation, relapse, and drug resistance. However, technical challenges still hinder a better understanding of the dynamics of distinctive phenotypic states and abnormal trajectories from normal physiological transition to malignant stages....]]></summary>
        <author>
            <name>Yuqing Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Melanoma clonal subline analysis uncovers heterogeneity-driven immunotherapy resistance mechanisms]]></title>
        <id>pubmed:37333132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37333132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) can promote cancer progression and treatment failure, but the complexity of the regulatory programs and contextual factors involved complicates its study. To understand the specific contribution of ITH to immune checkpoint blockade (ICB) response, we generated single cell-derived clonal sublines from an ICB-sensitive and genetically and phenotypically heterogeneous mouse melanoma model, M4. Genomic and single cell transcriptomic analyses uncovered the diversity...]]></summary>
        <author>
            <name>Charli Gruen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding: From developmental tracing to anti-tumor drug discovery]]></title>
        <id>pubmed:37336285</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37336285/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution has gained immense attention in explaining cancer cell status, history, and fate during cancer progression. Current single-cell or spatial transcriptome technologies have broadened our understanding of various mechanisms underlying cancer initiation, relapse, and drug resistance. However, technical challenges still hinder a better understanding of the dynamics of distinctive phenotypic states and abnormal trajectories from normal physiological transition to malignant stages....]]></summary>
        <author>
            <name>Yuqing Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Melanoma clonal subline analysis uncovers heterogeneity-driven immunotherapy resistance mechanisms]]></title>
        <id>pubmed:37333132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37333132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) can promote cancer progression and treatment failure, but the complexity of the regulatory programs and contextual factors involved complicates its study. To understand the specific contribution of ITH to immune checkpoint blockade (ICB) response, we generated single cell-derived clonal sublines from an ICB-sensitive and genetically and phenotypically heterogeneous mouse melanoma model, M4. Genomic and single cell transcriptomic analyses uncovered the diversity...]]></summary>
        <author>
            <name>Charli Gruen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding: From developmental tracing to anti-tumor drug discovery]]></title>
        <id>pubmed:37336285</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37336285/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution has gained immense attention in explaining cancer cell status, history, and fate during cancer progression. Current single-cell or spatial transcriptome technologies have broadened our understanding of various mechanisms underlying cancer initiation, relapse, and drug resistance. However, technical challenges still hinder a better understanding of the dynamics of distinctive phenotypic states and abnormal trajectories from normal physiological transition to malignant stages....]]></summary>
        <author>
            <name>Yuqing Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Melanoma clonal subline analysis uncovers heterogeneity-driven immunotherapy resistance mechanisms]]></title>
        <id>pubmed:37333132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37333132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) can promote cancer progression and treatment failure, but the complexity of the regulatory programs and contextual factors involved complicates its study. To understand the specific contribution of ITH to immune checkpoint blockade (ICB) response, we generated single cell-derived clonal sublines from an ICB-sensitive and genetically and phenotypically heterogeneous mouse melanoma model, M4. Genomic and single cell transcriptomic analyses uncovered the diversity...]]></summary>
        <author>
            <name>Charli Gruen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding: From developmental tracing to anti-tumor drug discovery]]></title>
        <id>pubmed:37336285</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37336285/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution has gained immense attention in explaining cancer cell status, history, and fate during cancer progression. Current single-cell or spatial transcriptome technologies have broadened our understanding of various mechanisms underlying cancer initiation, relapse, and drug resistance. However, technical challenges still hinder a better understanding of the dynamics of distinctive phenotypic states and abnormal trajectories from normal physiological transition to malignant stages....]]></summary>
        <author>
            <name>Yuqing Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Melanoma clonal subline analysis uncovers heterogeneity-driven immunotherapy resistance mechanisms]]></title>
        <id>pubmed:37333132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37333132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) can promote cancer progression and treatment failure, but the complexity of the regulatory programs and contextual factors involved complicates its study. To understand the specific contribution of ITH to immune checkpoint blockade (ICB) response, we generated single cell-derived clonal sublines from an ICB-sensitive and genetically and phenotypically heterogeneous mouse melanoma model, M4. Genomic and single cell transcriptomic analyses uncovered the diversity...]]></summary>
        <author>
            <name>Charli Gruen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding: From developmental tracing to anti-tumor drug discovery]]></title>
        <id>pubmed:37336285</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37336285/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution has gained immense attention in explaining cancer cell status, history, and fate during cancer progression. Current single-cell or spatial transcriptome technologies have broadened our understanding of various mechanisms underlying cancer initiation, relapse, and drug resistance. However, technical challenges still hinder a better understanding of the dynamics of distinctive phenotypic states and abnormal trajectories from normal physiological transition to malignant stages....]]></summary>
        <author>
            <name>Yuqing Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Melanoma clonal subline analysis uncovers heterogeneity-driven immunotherapy resistance mechanisms]]></title>
        <id>pubmed:37333132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37333132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) can promote cancer progression and treatment failure, but the complexity of the regulatory programs and contextual factors involved complicates its study. To understand the specific contribution of ITH to immune checkpoint blockade (ICB) response, we generated single cell-derived clonal sublines from an ICB-sensitive and genetically and phenotypically heterogeneous mouse melanoma model, M4. Genomic and single cell transcriptomic analyses uncovered the diversity...]]></summary>
        <author>
            <name>Charli Gruen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding: From developmental tracing to anti-tumor drug discovery]]></title>
        <id>pubmed:37336285</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37336285/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution has gained immense attention in explaining cancer cell status, history, and fate during cancer progression. Current single-cell or spatial transcriptome technologies have broadened our understanding of various mechanisms underlying cancer initiation, relapse, and drug resistance. However, technical challenges still hinder a better understanding of the dynamics of distinctive phenotypic states and abnormal trajectories from normal physiological transition to malignant stages....]]></summary>
        <author>
            <name>Yuqing Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Melanoma clonal subline analysis uncovers heterogeneity-driven immunotherapy resistance mechanisms]]></title>
        <id>pubmed:37333132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37333132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) can promote cancer progression and treatment failure, but the complexity of the regulatory programs and contextual factors involved complicates its study. To understand the specific contribution of ITH to immune checkpoint blockade (ICB) response, we generated single cell-derived clonal sublines from an ICB-sensitive and genetically and phenotypically heterogeneous mouse melanoma model, M4. Genomic and single cell transcriptomic analyses uncovered the diversity...]]></summary>
        <author>
            <name>Charli Gruen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cellular barcoding: From developmental tracing to anti-tumor drug discovery]]></title>
        <id>pubmed:37336285</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37336285/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution has gained immense attention in explaining cancer cell status, history, and fate during cancer progression. Current single-cell or spatial transcriptome technologies have broadened our understanding of various mechanisms underlying cancer initiation, relapse, and drug resistance. However, technical challenges still hinder a better understanding of the dynamics of distinctive phenotypic states and abnormal trajectories from normal physiological transition to malignant stages....]]></summary>
        <author>
            <name>Yuqing Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Melanoma clonal subline analysis uncovers heterogeneity-driven immunotherapy resistance mechanisms]]></title>
        <id>pubmed:37333132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37333132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) can promote cancer progression and treatment failure, but the complexity of the regulatory programs and contextual factors involved complicates its study. To understand the specific contribution of ITH to immune checkpoint blockade (ICB) response, we generated single cell-derived clonal sublines from an ICB-sensitive and genetically and phenotypically heterogeneous mouse melanoma model, M4. Genomic and single cell transcriptomic analyses uncovered the diversity...]]></summary>
        <author>
            <name>Charli Gruen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Melanoma clonal subline analysis uncovers heterogeneity-driven immunotherapy resistance mechanisms]]></title>
        <id>pubmed:37333132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37333132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumoral heterogeneity (ITH) can promote cancer progression and treatment failure, but the complexity of the regulatory programs and contextual factors involved complicates its study. To understand the specific contribution of ITH to immune checkpoint blockade (ICB) response, we generated single cell-derived clonal sublines from an ICB-sensitive and genetically and phenotypically heterogeneous mouse melanoma model, M4. Genomic and single cell transcriptomic analyses uncovered the diversity...]]></summary>
        <author>
            <name>Charli Gruen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology]]></title>
        <id>pubmed:37331781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37331781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent breakthroughs in circulating tumor DNA (ctDNA) technologies present a compelling opportunity to combine this emerging liquid biopsy approach with the field of radiogenomics, the study of how tumor genomics correlate with radiotherapy response and radiotoxicity. Canonically, ctDNA levels reflect metastatic tumor burden, although newer ultrasensitive technologies can be used after curative-intent radiotherapy of localized disease to assess ctDNA for minimal residual disease (MRD) detection...]]></summary>
        <author>
            <name>Noah Earland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology]]></title>
        <id>pubmed:37331781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37331781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent breakthroughs in circulating tumor DNA (ctDNA) technologies present a compelling opportunity to combine this emerging liquid biopsy approach with the field of radiogenomics, the study of how tumor genomics correlate with radiotherapy response and radiotoxicity. Canonically, ctDNA levels reflect metastatic tumor burden, although newer ultrasensitive technologies can be used after curative-intent radiotherapy of localized disease to assess ctDNA for minimal residual disease (MRD) detection...]]></summary>
        <author>
            <name>Noah Earland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology]]></title>
        <id>pubmed:37331781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37331781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent breakthroughs in circulating tumor DNA (ctDNA) technologies present a compelling opportunity to combine this emerging liquid biopsy approach with the field of radiogenomics, the study of how tumor genomics correlate with radiotherapy response and radiotoxicity. Canonically, ctDNA levels reflect metastatic tumor burden, although newer ultrasensitive technologies can be used after curative-intent radiotherapy of localized disease to assess ctDNA for minimal residual disease (MRD) detection...]]></summary>
        <author>
            <name>Noah Earland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology]]></title>
        <id>pubmed:37331781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37331781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent breakthroughs in circulating tumor DNA (ctDNA) technologies present a compelling opportunity to combine this emerging liquid biopsy approach with the field of radiogenomics, the study of how tumor genomics correlate with radiotherapy response and radiotoxicity. Canonically, ctDNA levels reflect metastatic tumor burden, although newer ultrasensitive technologies can be used after curative-intent radiotherapy of localized disease to assess ctDNA for minimal residual disease (MRD) detection...]]></summary>
        <author>
            <name>Noah Earland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology]]></title>
        <id>pubmed:37331781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37331781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent breakthroughs in circulating tumor DNA (ctDNA) technologies present a compelling opportunity to combine this emerging liquid biopsy approach with the field of radiogenomics, the study of how tumor genomics correlate with radiotherapy response and radiotoxicity. Canonically, ctDNA levels reflect metastatic tumor burden, although newer ultrasensitive technologies can be used after curative-intent radiotherapy of localized disease to assess ctDNA for minimal residual disease (MRD) detection...]]></summary>
        <author>
            <name>Noah Earland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology]]></title>
        <id>pubmed:37331781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37331781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent breakthroughs in circulating tumor DNA (ctDNA) technologies present a compelling opportunity to combine this emerging liquid biopsy approach with the field of radiogenomics, the study of how tumor genomics correlate with radiotherapy response and radiotoxicity. Canonically, ctDNA levels reflect metastatic tumor burden, although newer ultrasensitive technologies can be used after curative-intent radiotherapy of localized disease to assess ctDNA for minimal residual disease (MRD) detection...]]></summary>
        <author>
            <name>Noah Earland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology]]></title>
        <id>pubmed:37331781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37331781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent breakthroughs in circulating tumor DNA (ctDNA) technologies present a compelling opportunity to combine this emerging liquid biopsy approach with the field of radiogenomics, the study of how tumor genomics correlate with radiotherapy response and radiotoxicity. Canonically, ctDNA levels reflect metastatic tumor burden, although newer ultrasensitive technologies can be used after curative-intent radiotherapy of localized disease to assess ctDNA for minimal residual disease (MRD) detection...]]></summary>
        <author>
            <name>Noah Earland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology]]></title>
        <id>pubmed:37331781</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37331781/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent breakthroughs in circulating tumor DNA (ctDNA) technologies present a compelling opportunity to combine this emerging liquid biopsy approach with the field of radiogenomics, the study of how tumor genomics correlate with radiotherapy response and radiotoxicity. Canonically, ctDNA levels reflect metastatic tumor burden, although newer ultrasensitive technologies can be used after curative-intent radiotherapy of localized disease to assess ctDNA for minimal residual disease (MRD) detection...]]></summary>
        <author>
            <name>Noah Earland</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical trial designs for evaluating and exploiting cancer evolution]]></title>
        <id>pubmed:37331179</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37331179/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolution of drug-resistant cell subpopulations causes cancer treatment failure. Current preclinical evidence shows that it is possible to model herding of clonal evolution and collateral sensitivity where an initial treatment could favourably influence the response to a subsequent one. Novel therapy strategies exploiting this understanding are being considered, and clinical trial designs for steering cancer evolution are needed. Furthermore, preclinical evidence suggests that different...]]></summary>
        <author>
            <name>Alvaro H Ingles Garces</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical trial designs for evaluating and exploiting cancer evolution]]></title>
        <id>pubmed:37331179</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37331179/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolution of drug-resistant cell subpopulations causes cancer treatment failure. Current preclinical evidence shows that it is possible to model herding of clonal evolution and collateral sensitivity where an initial treatment could favourably influence the response to a subsequent one. Novel therapy strategies exploiting this understanding are being considered, and clinical trial designs for steering cancer evolution are needed. Furthermore, preclinical evidence suggests that different...]]></summary>
        <author>
            <name>Alvaro H Ingles Garces</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical trial designs for evaluating and exploiting cancer evolution]]></title>
        <id>pubmed:37331179</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37331179/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolution of drug-resistant cell subpopulations causes cancer treatment failure. Current preclinical evidence shows that it is possible to model herding of clonal evolution and collateral sensitivity where an initial treatment could favourably influence the response to a subsequent one. Novel therapy strategies exploiting this understanding are being considered, and clinical trial designs for steering cancer evolution are needed. Furthermore, preclinical evidence suggests that different...]]></summary>
        <author>
            <name>Alvaro H Ingles Garces</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical trial designs for evaluating and exploiting cancer evolution]]></title>
        <id>pubmed:37331179</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37331179/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolution of drug-resistant cell subpopulations causes cancer treatment failure. Current preclinical evidence shows that it is possible to model herding of clonal evolution and collateral sensitivity where an initial treatment could favourably influence the response to a subsequent one. Novel therapy strategies exploiting this understanding are being considered, and clinical trial designs for steering cancer evolution are needed. Furthermore, preclinical evidence suggests that different...]]></summary>
        <author>
            <name>Alvaro H Ingles Garces</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical trial designs for evaluating and exploiting cancer evolution]]></title>
        <id>pubmed:37331179</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37331179/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolution of drug-resistant cell subpopulations causes cancer treatment failure. Current preclinical evidence shows that it is possible to model herding of clonal evolution and collateral sensitivity where an initial treatment could favourably influence the response to a subsequent one. Novel therapy strategies exploiting this understanding are being considered, and clinical trial designs for steering cancer evolution are needed. Furthermore, preclinical evidence suggests that different...]]></summary>
        <author>
            <name>Alvaro H Ingles Garces</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical trial designs for evaluating and exploiting cancer evolution]]></title>
        <id>pubmed:37331179</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37331179/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolution of drug-resistant cell subpopulations causes cancer treatment failure. Current preclinical evidence shows that it is possible to model herding of clonal evolution and collateral sensitivity where an initial treatment could favourably influence the response to a subsequent one. Novel therapy strategies exploiting this understanding are being considered, and clinical trial designs for steering cancer evolution are needed. Furthermore, preclinical evidence suggests that different...]]></summary>
        <author>
            <name>Alvaro H Ingles Garces</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical trial designs for evaluating and exploiting cancer evolution]]></title>
        <id>pubmed:37331179</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37331179/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolution of drug-resistant cell subpopulations causes cancer treatment failure. Current preclinical evidence shows that it is possible to model herding of clonal evolution and collateral sensitivity where an initial treatment could favourably influence the response to a subsequent one. Novel therapy strategies exploiting this understanding are being considered, and clinical trial designs for steering cancer evolution are needed. Furthermore, preclinical evidence suggests that different...]]></summary>
        <author>
            <name>Alvaro H Ingles Garces</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical trial designs for evaluating and exploiting cancer evolution]]></title>
        <id>pubmed:37331179</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37331179/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The evolution of drug-resistant cell subpopulations causes cancer treatment failure. Current preclinical evidence shows that it is possible to model herding of clonal evolution and collateral sensitivity where an initial treatment could favourably influence the response to a subsequent one. Novel therapy strategies exploiting this understanding are being considered, and clinical trial designs for steering cancer evolution are needed. Furthermore, preclinical evidence suggests that different...]]></summary>
        <author>
            <name>Alvaro H Ingles Garces</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pure red cell aplasia: the second hundred years]]></title>
        <id>pubmed:37327996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pure red cell aplasia (PRCA) is a rare hematologic syndrome, characterized by an isolated normocytic anemia with severe reticulocytopenia, and defined by absence or near absence of erythroid precursors in the bone marrow. First described in 1922, PRCA may be a primary autoimmune or clonal myeloid or lymphoid disorder, but may also be secondary to other disorders of immune dysregulation/autoimmunity, to infections, to neoplasms, or to drugs. Insights from the study of PRCA have helped illuminate...]]></summary>
        <author>
            <name>Robert T Means</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression]]></title>
        <id>pubmed:37327320</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327320/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Purpose To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms of resistance to PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Patients and Methods We used targeted sequencing (TS) to analyse 78 longitudinal cfDNA samples collected from 30 patients with HGSOC enrolled in a phase II clinical trial evaluating cediranib (VEGF inhibitor) plus olaparib (PARPi) after progression on PARPi alone. cfDNA was collected at baseline, before treatment cycle 2,...]]></summary>
        <author>
            <name>Stephanie Lheureux</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pure red cell aplasia: the second hundred years]]></title>
        <id>pubmed:37327996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pure red cell aplasia (PRCA) is a rare hematologic syndrome, characterized by an isolated normocytic anemia with severe reticulocytopenia, and defined by absence or near absence of erythroid precursors in the bone marrow. First described in 1922, PRCA may be a primary autoimmune or clonal myeloid or lymphoid disorder, but may also be secondary to other disorders of immune dysregulation/autoimmunity, to infections, to neoplasms, or to drugs. Insights from the study of PRCA have helped illuminate...]]></summary>
        <author>
            <name>Robert T Means</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression]]></title>
        <id>pubmed:37327320</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327320/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Purpose To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms of resistance to PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Patients and Methods We used targeted sequencing (TS) to analyse 78 longitudinal cfDNA samples collected from 30 patients with HGSOC enrolled in a phase II clinical trial evaluating cediranib (VEGF inhibitor) plus olaparib (PARPi) after progression on PARPi alone. cfDNA was collected at baseline, before treatment cycle 2,...]]></summary>
        <author>
            <name>Stephanie Lheureux</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pure red cell aplasia: the second hundred years]]></title>
        <id>pubmed:37327996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pure red cell aplasia (PRCA) is a rare hematologic syndrome, characterized by an isolated normocytic anemia with severe reticulocytopenia, and defined by absence or near absence of erythroid precursors in the bone marrow. First described in 1922, PRCA may be a primary autoimmune or clonal myeloid or lymphoid disorder, but may also be secondary to other disorders of immune dysregulation/autoimmunity, to infections, to neoplasms, or to drugs. Insights from the study of PRCA have helped illuminate...]]></summary>
        <author>
            <name>Robert T Means</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression]]></title>
        <id>pubmed:37327320</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327320/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Purpose To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms of resistance to PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Patients and Methods We used targeted sequencing (TS) to analyse 78 longitudinal cfDNA samples collected from 30 patients with HGSOC enrolled in a phase II clinical trial evaluating cediranib (VEGF inhibitor) plus olaparib (PARPi) after progression on PARPi alone. cfDNA was collected at baseline, before treatment cycle 2,...]]></summary>
        <author>
            <name>Stephanie Lheureux</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pure red cell aplasia: the second hundred years]]></title>
        <id>pubmed:37327996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pure red cell aplasia (PRCA) is a rare hematologic syndrome, characterized by an isolated normocytic anemia with severe reticulocytopenia, and defined by absence or near absence of erythroid precursors in the bone marrow. First described in 1922, PRCA may be a primary autoimmune or clonal myeloid or lymphoid disorder, but may also be secondary to other disorders of immune dysregulation/autoimmunity, to infections, to neoplasms, or to drugs. Insights from the study of PRCA have helped illuminate...]]></summary>
        <author>
            <name>Robert T Means</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression]]></title>
        <id>pubmed:37327320</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327320/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Purpose To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms of resistance to PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Patients and Methods We used targeted sequencing (TS) to analyse 78 longitudinal cfDNA samples collected from 30 patients with HGSOC enrolled in a phase II clinical trial evaluating cediranib (VEGF inhibitor) plus olaparib (PARPi) after progression on PARPi alone. cfDNA was collected at baseline, before treatment cycle 2,...]]></summary>
        <author>
            <name>Stephanie Lheureux</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pure red cell aplasia: the second hundred years]]></title>
        <id>pubmed:37327996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pure red cell aplasia (PRCA) is a rare hematologic syndrome, characterized by an isolated normocytic anemia with severe reticulocytopenia, and defined by absence or near absence of erythroid precursors in the bone marrow. First described in 1922, PRCA may be a primary autoimmune or clonal myeloid or lymphoid disorder, but may also be secondary to other disorders of immune dysregulation/autoimmunity, to infections, to neoplasms, or to drugs. Insights from the study of PRCA have helped illuminate...]]></summary>
        <author>
            <name>Robert T Means</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression]]></title>
        <id>pubmed:37327320</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327320/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Purpose To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms of resistance to PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Patients and Methods We used targeted sequencing (TS) to analyse 78 longitudinal cfDNA samples collected from 30 patients with HGSOC enrolled in a phase II clinical trial evaluating cediranib (VEGF inhibitor) plus olaparib (PARPi) after progression on PARPi alone. cfDNA was collected at baseline, before treatment cycle 2,...]]></summary>
        <author>
            <name>Stephanie Lheureux</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pure red cell aplasia: the second hundred years]]></title>
        <id>pubmed:37327996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pure red cell aplasia (PRCA) is a rare hematologic syndrome, characterized by an isolated normocytic anemia with severe reticulocytopenia, and defined by absence or near absence of erythroid precursors in the bone marrow. First described in 1922, PRCA may be a primary autoimmune or clonal myeloid or lymphoid disorder, but may also be secondary to other disorders of immune dysregulation/autoimmunity, to infections, to neoplasms, or to drugs. Insights from the study of PRCA have helped illuminate...]]></summary>
        <author>
            <name>Robert T Means</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression]]></title>
        <id>pubmed:37327320</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327320/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Purpose To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms of resistance to PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Patients and Methods We used targeted sequencing (TS) to analyse 78 longitudinal cfDNA samples collected from 30 patients with HGSOC enrolled in a phase II clinical trial evaluating cediranib (VEGF inhibitor) plus olaparib (PARPi) after progression on PARPi alone. cfDNA was collected at baseline, before treatment cycle 2,...]]></summary>
        <author>
            <name>Stephanie Lheureux</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pure red cell aplasia: the second hundred years]]></title>
        <id>pubmed:37327996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pure red cell aplasia (PRCA) is a rare hematologic syndrome, characterized by an isolated normocytic anemia with severe reticulocytopenia, and defined by absence or near absence of erythroid precursors in the bone marrow. First described in 1922, PRCA may be a primary autoimmune or clonal myeloid or lymphoid disorder, but may also be secondary to other disorders of immune dysregulation/autoimmunity, to infections, to neoplasms, or to drugs. Insights from the study of PRCA have helped illuminate...]]></summary>
        <author>
            <name>Robert T Means</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression]]></title>
        <id>pubmed:37327320</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327320/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Purpose To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms of resistance to PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Patients and Methods We used targeted sequencing (TS) to analyse 78 longitudinal cfDNA samples collected from 30 patients with HGSOC enrolled in a phase II clinical trial evaluating cediranib (VEGF inhibitor) plus olaparib (PARPi) after progression on PARPi alone. cfDNA was collected at baseline, before treatment cycle 2,...]]></summary>
        <author>
            <name>Stephanie Lheureux</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pure red cell aplasia: the second hundred years]]></title>
        <id>pubmed:37327996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pure red cell aplasia (PRCA) is a rare hematologic syndrome, characterized by an isolated normocytic anemia with severe reticulocytopenia, and defined by absence or near absence of erythroid precursors in the bone marrow. First described in 1922, PRCA may be a primary autoimmune or clonal myeloid or lymphoid disorder, but may also be secondary to other disorders of immune dysregulation/autoimmunity, to infections, to neoplasms, or to drugs. Insights from the study of PRCA have helped illuminate...]]></summary>
        <author>
            <name>Robert T Means</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression]]></title>
        <id>pubmed:37327320</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327320/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Purpose To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms of resistance to PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Patients and Methods We used targeted sequencing (TS) to analyse 78 longitudinal cfDNA samples collected from 30 patients with HGSOC enrolled in a phase II clinical trial evaluating cediranib (VEGF inhibitor) plus olaparib (PARPi) after progression on PARPi alone. cfDNA was collected at baseline, before treatment cycle 2,...]]></summary>
        <author>
            <name>Stephanie Lheureux</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pure red cell aplasia: the second hundred years]]></title>
        <id>pubmed:37327996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pure red cell aplasia (PRCA) is a rare hematologic syndrome, characterized by an isolated normocytic anemia with severe reticulocytopenia, and defined by absence or near absence of erythroid precursors in the bone marrow. First described in 1922, PRCA may be a primary autoimmune or clonal myeloid or lymphoid disorder, but may also be secondary to other disorders of immune dysregulation/autoimmunity, to infections, to neoplasms, or to drugs. Insights from the study of PRCA have helped illuminate...]]></summary>
        <author>
            <name>Robert T Means</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression]]></title>
        <id>pubmed:37327320</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327320/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Purpose To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms of resistance to PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Patients and Methods We used targeted sequencing (TS) to analyse 78 longitudinal cfDNA samples collected from 30 patients with HGSOC enrolled in a phase II clinical trial evaluating cediranib (VEGF inhibitor) plus olaparib (PARPi) after progression on PARPi alone. cfDNA was collected at baseline, before treatment cycle 2,...]]></summary>
        <author>
            <name>Stephanie Lheureux</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Pure red cell aplasia: the second hundred years]]></title>
        <id>pubmed:37327996</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327996/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pure red cell aplasia (PRCA) is a rare hematologic syndrome, characterized by an isolated normocytic anemia with severe reticulocytopenia, and defined by absence or near absence of erythroid precursors in the bone marrow. First described in 1922, PRCA may be a primary autoimmune or clonal myeloid or lymphoid disorder, but may also be secondary to other disorders of immune dysregulation/autoimmunity, to infections, to neoplasms, or to drugs. Insights from the study of PRCA have helped illuminate...]]></summary>
        <author>
            <name>Robert T Means</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression]]></title>
        <id>pubmed:37327320</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327320/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Purpose To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms of resistance to PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Patients and Methods We used targeted sequencing (TS) to analyse 78 longitudinal cfDNA samples collected from 30 patients with HGSOC enrolled in a phase II clinical trial evaluating cediranib (VEGF inhibitor) plus olaparib (PARPi) after progression on PARPi alone. cfDNA was collected at baseline, before treatment cycle 2,...]]></summary>
        <author>
            <name>Stephanie Lheureux</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying mechanisms of resistance by circulating tumour DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at time of PARP Inhibitor Progression]]></title>
        <id>pubmed:37327320</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37327320/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Purpose To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms of resistance to PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Patients and Methods We used targeted sequencing (TS) to analyse 78 longitudinal cfDNA samples collected from 30 patients with HGSOC enrolled in a phase II clinical trial evaluating cediranib (VEGF inhibitor) plus olaparib (PARPi) after progression on PARPi alone. cfDNA was collected at baseline, before treatment cycle 2,...]]></summary>
        <author>
            <name>Stephanie Lheureux</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol]]></title>
        <id>pubmed:37328818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors. However, the recurence rate at...]]></summary>
        <author>
            <name>Lionnel Geoffrois</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer genomes tolerate deleterious coding mutations through somatic copy number amplifications of wild-type regions]]></title>
        <id>pubmed:37328455</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328455/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers evolve under the accumulation of thousands of somatic mutations and chromosomal aberrations. While most coding mutations are deleterious, almost all protein-coding genes lack detectable signals of negative selection. This raises the question of how tumors tolerate such large amounts of deleterious mutations. Using 8,690 tumor samples from The Cancer Genome Atlas, we demonstrate that copy number amplifications frequently cover haploinsufficient genes in mutation-prone regions. This could...]]></summary>
        <author>
            <name>Fabio Alfieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms]]></title>
        <id>pubmed:37323185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroendocrine neoplasms (NENs) are initially monoclonal neoplasms that progressively become polyclonal, with very different genotypic and phenotypic characteristics leading to biological differences, including the Ki-67 proliferation index, morphology, or sensitivity to treatments. Whereas inter-patient heterogeneity has been well described, intra-tumor heterogeneity has been little studied. However, NENs present a high degree of heterogeneity, both spatially within the same location or between...]]></summary>
        <author>
            <name>Pauline Bourdeleau</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic alterations dissection revealed <em>MUC4</em> mutation as a potential driver in lung adenocarcinoma local recurrence]]></title>
        <id>pubmed:37323170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Genomic alteration landscape was changing during LUAD recurrence to construct a more suitable environment for the survival of tumor cells. Several potential driver mutations and targets during LUAD recurrence were identified, such as MUC4, and more investigation was needed to verify the specific functions and roles.]]></summary>
        <author>
            <name>Chongze Yuan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol]]></title>
        <id>pubmed:37328818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors. However, the recurence rate at...]]></summary>
        <author>
            <name>Lionnel Geoffrois</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer genomes tolerate deleterious coding mutations through somatic copy number amplifications of wild-type regions]]></title>
        <id>pubmed:37328455</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328455/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers evolve under the accumulation of thousands of somatic mutations and chromosomal aberrations. While most coding mutations are deleterious, almost all protein-coding genes lack detectable signals of negative selection. This raises the question of how tumors tolerate such large amounts of deleterious mutations. Using 8,690 tumor samples from The Cancer Genome Atlas, we demonstrate that copy number amplifications frequently cover haploinsufficient genes in mutation-prone regions. This could...]]></summary>
        <author>
            <name>Fabio Alfieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms]]></title>
        <id>pubmed:37323185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroendocrine neoplasms (NENs) are initially monoclonal neoplasms that progressively become polyclonal, with very different genotypic and phenotypic characteristics leading to biological differences, including the Ki-67 proliferation index, morphology, or sensitivity to treatments. Whereas inter-patient heterogeneity has been well described, intra-tumor heterogeneity has been little studied. However, NENs present a high degree of heterogeneity, both spatially within the same location or between...]]></summary>
        <author>
            <name>Pauline Bourdeleau</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic alterations dissection revealed <em>MUC4</em> mutation as a potential driver in lung adenocarcinoma local recurrence]]></title>
        <id>pubmed:37323170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Genomic alteration landscape was changing during LUAD recurrence to construct a more suitable environment for the survival of tumor cells. Several potential driver mutations and targets during LUAD recurrence were identified, such as MUC4, and more investigation was needed to verify the specific functions and roles.]]></summary>
        <author>
            <name>Chongze Yuan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol]]></title>
        <id>pubmed:37328818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors. However, the recurence rate at...]]></summary>
        <author>
            <name>Lionnel Geoffrois</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer genomes tolerate deleterious coding mutations through somatic copy number amplifications of wild-type regions]]></title>
        <id>pubmed:37328455</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328455/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers evolve under the accumulation of thousands of somatic mutations and chromosomal aberrations. While most coding mutations are deleterious, almost all protein-coding genes lack detectable signals of negative selection. This raises the question of how tumors tolerate such large amounts of deleterious mutations. Using 8,690 tumor samples from The Cancer Genome Atlas, we demonstrate that copy number amplifications frequently cover haploinsufficient genes in mutation-prone regions. This could...]]></summary>
        <author>
            <name>Fabio Alfieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms]]></title>
        <id>pubmed:37323185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroendocrine neoplasms (NENs) are initially monoclonal neoplasms that progressively become polyclonal, with very different genotypic and phenotypic characteristics leading to biological differences, including the Ki-67 proliferation index, morphology, or sensitivity to treatments. Whereas inter-patient heterogeneity has been well described, intra-tumor heterogeneity has been little studied. However, NENs present a high degree of heterogeneity, both spatially within the same location or between...]]></summary>
        <author>
            <name>Pauline Bourdeleau</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic alterations dissection revealed <em>MUC4</em> mutation as a potential driver in lung adenocarcinoma local recurrence]]></title>
        <id>pubmed:37323170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Genomic alteration landscape was changing during LUAD recurrence to construct a more suitable environment for the survival of tumor cells. Several potential driver mutations and targets during LUAD recurrence were identified, such as MUC4, and more investigation was needed to verify the specific functions and roles.]]></summary>
        <author>
            <name>Chongze Yuan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol]]></title>
        <id>pubmed:37328818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors. However, the recurence rate at...]]></summary>
        <author>
            <name>Lionnel Geoffrois</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer genomes tolerate deleterious coding mutations through somatic copy number amplifications of wild-type regions]]></title>
        <id>pubmed:37328455</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328455/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers evolve under the accumulation of thousands of somatic mutations and chromosomal aberrations. While most coding mutations are deleterious, almost all protein-coding genes lack detectable signals of negative selection. This raises the question of how tumors tolerate such large amounts of deleterious mutations. Using 8,690 tumor samples from The Cancer Genome Atlas, we demonstrate that copy number amplifications frequently cover haploinsufficient genes in mutation-prone regions. This could...]]></summary>
        <author>
            <name>Fabio Alfieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms]]></title>
        <id>pubmed:37323185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroendocrine neoplasms (NENs) are initially monoclonal neoplasms that progressively become polyclonal, with very different genotypic and phenotypic characteristics leading to biological differences, including the Ki-67 proliferation index, morphology, or sensitivity to treatments. Whereas inter-patient heterogeneity has been well described, intra-tumor heterogeneity has been little studied. However, NENs present a high degree of heterogeneity, both spatially within the same location or between...]]></summary>
        <author>
            <name>Pauline Bourdeleau</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic alterations dissection revealed <em>MUC4</em> mutation as a potential driver in lung adenocarcinoma local recurrence]]></title>
        <id>pubmed:37323170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Genomic alteration landscape was changing during LUAD recurrence to construct a more suitable environment for the survival of tumor cells. Several potential driver mutations and targets during LUAD recurrence were identified, such as MUC4, and more investigation was needed to verify the specific functions and roles.]]></summary>
        <author>
            <name>Chongze Yuan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol]]></title>
        <id>pubmed:37328818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors. However, the recurence rate at...]]></summary>
        <author>
            <name>Lionnel Geoffrois</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer genomes tolerate deleterious coding mutations through somatic copy number amplifications of wild-type regions]]></title>
        <id>pubmed:37328455</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328455/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers evolve under the accumulation of thousands of somatic mutations and chromosomal aberrations. While most coding mutations are deleterious, almost all protein-coding genes lack detectable signals of negative selection. This raises the question of how tumors tolerate such large amounts of deleterious mutations. Using 8,690 tumor samples from The Cancer Genome Atlas, we demonstrate that copy number amplifications frequently cover haploinsufficient genes in mutation-prone regions. This could...]]></summary>
        <author>
            <name>Fabio Alfieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms]]></title>
        <id>pubmed:37323185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroendocrine neoplasms (NENs) are initially monoclonal neoplasms that progressively become polyclonal, with very different genotypic and phenotypic characteristics leading to biological differences, including the Ki-67 proliferation index, morphology, or sensitivity to treatments. Whereas inter-patient heterogeneity has been well described, intra-tumor heterogeneity has been little studied. However, NENs present a high degree of heterogeneity, both spatially within the same location or between...]]></summary>
        <author>
            <name>Pauline Bourdeleau</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic alterations dissection revealed <em>MUC4</em> mutation as a potential driver in lung adenocarcinoma local recurrence]]></title>
        <id>pubmed:37323170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Genomic alteration landscape was changing during LUAD recurrence to construct a more suitable environment for the survival of tumor cells. Several potential driver mutations and targets during LUAD recurrence were identified, such as MUC4, and more investigation was needed to verify the specific functions and roles.]]></summary>
        <author>
            <name>Chongze Yuan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol]]></title>
        <id>pubmed:37328818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors. However, the recurence rate at...]]></summary>
        <author>
            <name>Lionnel Geoffrois</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer genomes tolerate deleterious coding mutations through somatic copy number amplifications of wild-type regions]]></title>
        <id>pubmed:37328455</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328455/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers evolve under the accumulation of thousands of somatic mutations and chromosomal aberrations. While most coding mutations are deleterious, almost all protein-coding genes lack detectable signals of negative selection. This raises the question of how tumors tolerate such large amounts of deleterious mutations. Using 8,690 tumor samples from The Cancer Genome Atlas, we demonstrate that copy number amplifications frequently cover haploinsufficient genes in mutation-prone regions. This could...]]></summary>
        <author>
            <name>Fabio Alfieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms]]></title>
        <id>pubmed:37323185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroendocrine neoplasms (NENs) are initially monoclonal neoplasms that progressively become polyclonal, with very different genotypic and phenotypic characteristics leading to biological differences, including the Ki-67 proliferation index, morphology, or sensitivity to treatments. Whereas inter-patient heterogeneity has been well described, intra-tumor heterogeneity has been little studied. However, NENs present a high degree of heterogeneity, both spatially within the same location or between...]]></summary>
        <author>
            <name>Pauline Bourdeleau</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic alterations dissection revealed <em>MUC4</em> mutation as a potential driver in lung adenocarcinoma local recurrence]]></title>
        <id>pubmed:37323170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Genomic alteration landscape was changing during LUAD recurrence to construct a more suitable environment for the survival of tumor cells. Several potential driver mutations and targets during LUAD recurrence were identified, such as MUC4, and more investigation was needed to verify the specific functions and roles.]]></summary>
        <author>
            <name>Chongze Yuan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol]]></title>
        <id>pubmed:37328818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors. However, the recurence rate at...]]></summary>
        <author>
            <name>Lionnel Geoffrois</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer genomes tolerate deleterious coding mutations through somatic copy number amplifications of wild-type regions]]></title>
        <id>pubmed:37328455</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328455/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers evolve under the accumulation of thousands of somatic mutations and chromosomal aberrations. While most coding mutations are deleterious, almost all protein-coding genes lack detectable signals of negative selection. This raises the question of how tumors tolerate such large amounts of deleterious mutations. Using 8,690 tumor samples from The Cancer Genome Atlas, we demonstrate that copy number amplifications frequently cover haploinsufficient genes in mutation-prone regions. This could...]]></summary>
        <author>
            <name>Fabio Alfieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms]]></title>
        <id>pubmed:37323185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroendocrine neoplasms (NENs) are initially monoclonal neoplasms that progressively become polyclonal, with very different genotypic and phenotypic characteristics leading to biological differences, including the Ki-67 proliferation index, morphology, or sensitivity to treatments. Whereas inter-patient heterogeneity has been well described, intra-tumor heterogeneity has been little studied. However, NENs present a high degree of heterogeneity, both spatially within the same location or between...]]></summary>
        <author>
            <name>Pauline Bourdeleau</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic alterations dissection revealed <em>MUC4</em> mutation as a potential driver in lung adenocarcinoma local recurrence]]></title>
        <id>pubmed:37323170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Genomic alteration landscape was changing during LUAD recurrence to construct a more suitable environment for the survival of tumor cells. Several potential driver mutations and targets during LUAD recurrence were identified, such as MUC4, and more investigation was needed to verify the specific functions and roles.]]></summary>
        <author>
            <name>Chongze Yuan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol]]></title>
        <id>pubmed:37328818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors. However, the recurence rate at...]]></summary>
        <author>
            <name>Lionnel Geoffrois</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer genomes tolerate deleterious coding mutations through somatic copy number amplifications of wild-type regions]]></title>
        <id>pubmed:37328455</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328455/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers evolve under the accumulation of thousands of somatic mutations and chromosomal aberrations. While most coding mutations are deleterious, almost all protein-coding genes lack detectable signals of negative selection. This raises the question of how tumors tolerate such large amounts of deleterious mutations. Using 8,690 tumor samples from The Cancer Genome Atlas, we demonstrate that copy number amplifications frequently cover haploinsufficient genes in mutation-prone regions. This could...]]></summary>
        <author>
            <name>Fabio Alfieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms]]></title>
        <id>pubmed:37323185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroendocrine neoplasms (NENs) are initially monoclonal neoplasms that progressively become polyclonal, with very different genotypic and phenotypic characteristics leading to biological differences, including the Ki-67 proliferation index, morphology, or sensitivity to treatments. Whereas inter-patient heterogeneity has been well described, intra-tumor heterogeneity has been little studied. However, NENs present a high degree of heterogeneity, both spatially within the same location or between...]]></summary>
        <author>
            <name>Pauline Bourdeleau</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic alterations dissection revealed <em>MUC4</em> mutation as a potential driver in lung adenocarcinoma local recurrence]]></title>
        <id>pubmed:37323170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Genomic alteration landscape was changing during LUAD recurrence to construct a more suitable environment for the survival of tumor cells. Several potential driver mutations and targets during LUAD recurrence were identified, such as MUC4, and more investigation was needed to verify the specific functions and roles.]]></summary>
        <author>
            <name>Chongze Yuan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol]]></title>
        <id>pubmed:37328818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors. However, the recurence rate at...]]></summary>
        <author>
            <name>Lionnel Geoffrois</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer genomes tolerate deleterious coding mutations through somatic copy number amplifications of wild-type regions]]></title>
        <id>pubmed:37328455</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328455/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers evolve under the accumulation of thousands of somatic mutations and chromosomal aberrations. While most coding mutations are deleterious, almost all protein-coding genes lack detectable signals of negative selection. This raises the question of how tumors tolerate such large amounts of deleterious mutations. Using 8,690 tumor samples from The Cancer Genome Atlas, we demonstrate that copy number amplifications frequently cover haploinsufficient genes in mutation-prone regions. This could...]]></summary>
        <author>
            <name>Fabio Alfieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms]]></title>
        <id>pubmed:37323185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroendocrine neoplasms (NENs) are initially monoclonal neoplasms that progressively become polyclonal, with very different genotypic and phenotypic characteristics leading to biological differences, including the Ki-67 proliferation index, morphology, or sensitivity to treatments. Whereas inter-patient heterogeneity has been well described, intra-tumor heterogeneity has been little studied. However, NENs present a high degree of heterogeneity, both spatially within the same location or between...]]></summary>
        <author>
            <name>Pauline Bourdeleau</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic alterations dissection revealed <em>MUC4</em> mutation as a potential driver in lung adenocarcinoma local recurrence]]></title>
        <id>pubmed:37323170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Genomic alteration landscape was changing during LUAD recurrence to construct a more suitable environment for the survival of tumor cells. Several potential driver mutations and targets during LUAD recurrence were identified, such as MUC4, and more investigation was needed to verify the specific functions and roles.]]></summary>
        <author>
            <name>Chongze Yuan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Personalized follow-up of circulating DNA in resected stage III/IV melanoma: PERCIMEL multicentric prospective study protocol]]></title>
        <id>pubmed:37328818</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328818/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resectable metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors. However, the recurence rate at...]]></summary>
        <author>
            <name>Lionnel Geoffrois</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Cancer genomes tolerate deleterious coding mutations through somatic copy number amplifications of wild-type regions]]></title>
        <id>pubmed:37328455</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37328455/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers evolve under the accumulation of thousands of somatic mutations and chromosomal aberrations. While most coding mutations are deleterious, almost all protein-coding genes lack detectable signals of negative selection. This raises the question of how tumors tolerate such large amounts of deleterious mutations. Using 8,690 tumor samples from The Cancer Genome Atlas, we demonstrate that copy number amplifications frequently cover haploinsufficient genes in mutation-prone regions. This could...]]></summary>
        <author>
            <name>Fabio Alfieri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms]]></title>
        <id>pubmed:37323185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroendocrine neoplasms (NENs) are initially monoclonal neoplasms that progressively become polyclonal, with very different genotypic and phenotypic characteristics leading to biological differences, including the Ki-67 proliferation index, morphology, or sensitivity to treatments. Whereas inter-patient heterogeneity has been well described, intra-tumor heterogeneity has been little studied. However, NENs present a high degree of heterogeneity, both spatially within the same location or between...]]></summary>
        <author>
            <name>Pauline Bourdeleau</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic alterations dissection revealed <em>MUC4</em> mutation as a potential driver in lung adenocarcinoma local recurrence]]></title>
        <id>pubmed:37323170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Genomic alteration landscape was changing during LUAD recurrence to construct a more suitable environment for the survival of tumor cells. Several potential driver mutations and targets during LUAD recurrence were identified, such as MUC4, and more investigation was needed to verify the specific functions and roles.]]></summary>
        <author>
            <name>Chongze Yuan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms]]></title>
        <id>pubmed:37323185</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323185/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Neuroendocrine neoplasms (NENs) are initially monoclonal neoplasms that progressively become polyclonal, with very different genotypic and phenotypic characteristics leading to biological differences, including the Ki-67 proliferation index, morphology, or sensitivity to treatments. Whereas inter-patient heterogeneity has been well described, intra-tumor heterogeneity has been little studied. However, NENs present a high degree of heterogeneity, both spatially within the same location or between...]]></summary>
        <author>
            <name>Pauline Bourdeleau</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic alterations dissection revealed <em>MUC4</em> mutation as a potential driver in lung adenocarcinoma local recurrence]]></title>
        <id>pubmed:37323170</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37323170/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Genomic alteration landscape was changing during LUAD recurrence to construct a more suitable environment for the survival of tumor cells. Several potential driver mutations and targets during LUAD recurrence were identified, such as MUC4, and more investigation was needed to verify the specific functions and roles.]]></summary>
        <author>
            <name>Chongze Yuan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is associated with protection from Alzheimer's disease]]></title>
        <id>pubmed:37322115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37322115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a premalignant expansion of mutated hematopoietic stem cells. As CHIP-associated mutations are known to alter the development and function of myeloid cells, we hypothesized that CHIP may also be associated with the risk of Alzheimer's disease (AD), a disease in which brain-resident myeloid cells are thought to have a major role. To perform association tests between CHIP and AD dementia, we analyzed blood DNA sequencing data from 1,362...]]></summary>
        <author>
            <name>Hind Bouzid</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is associated with protection from Alzheimer's disease]]></title>
        <id>pubmed:37322115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37322115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a premalignant expansion of mutated hematopoietic stem cells. As CHIP-associated mutations are known to alter the development and function of myeloid cells, we hypothesized that CHIP may also be associated with the risk of Alzheimer's disease (AD), a disease in which brain-resident myeloid cells are thought to have a major role. To perform association tests between CHIP and AD dementia, we analyzed blood DNA sequencing data from 1,362...]]></summary>
        <author>
            <name>Hind Bouzid</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is associated with protection from Alzheimer's disease]]></title>
        <id>pubmed:37322115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37322115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a premalignant expansion of mutated hematopoietic stem cells. As CHIP-associated mutations are known to alter the development and function of myeloid cells, we hypothesized that CHIP may also be associated with the risk of Alzheimer's disease (AD), a disease in which brain-resident myeloid cells are thought to have a major role. To perform association tests between CHIP and AD dementia, we analyzed blood DNA sequencing data from 1,362...]]></summary>
        <author>
            <name>Hind Bouzid</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is associated with protection from Alzheimer's disease]]></title>
        <id>pubmed:37322115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37322115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a premalignant expansion of mutated hematopoietic stem cells. As CHIP-associated mutations are known to alter the development and function of myeloid cells, we hypothesized that CHIP may also be associated with the risk of Alzheimer's disease (AD), a disease in which brain-resident myeloid cells are thought to have a major role. To perform association tests between CHIP and AD dementia, we analyzed blood DNA sequencing data from 1,362...]]></summary>
        <author>
            <name>Hind Bouzid</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is associated with protection from Alzheimer's disease]]></title>
        <id>pubmed:37322115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37322115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a premalignant expansion of mutated hematopoietic stem cells. As CHIP-associated mutations are known to alter the development and function of myeloid cells, we hypothesized that CHIP may also be associated with the risk of Alzheimer's disease (AD), a disease in which brain-resident myeloid cells are thought to have a major role. To perform association tests between CHIP and AD dementia, we analyzed blood DNA sequencing data from 1,362...]]></summary>
        <author>
            <name>Hind Bouzid</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is associated with protection from Alzheimer's disease]]></title>
        <id>pubmed:37322115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37322115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a premalignant expansion of mutated hematopoietic stem cells. As CHIP-associated mutations are known to alter the development and function of myeloid cells, we hypothesized that CHIP may also be associated with the risk of Alzheimer's disease (AD), a disease in which brain-resident myeloid cells are thought to have a major role. To perform association tests between CHIP and AD dementia, we analyzed blood DNA sequencing data from 1,362...]]></summary>
        <author>
            <name>Hind Bouzid</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is associated with protection from Alzheimer's disease]]></title>
        <id>pubmed:37322115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37322115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a premalignant expansion of mutated hematopoietic stem cells. As CHIP-associated mutations are known to alter the development and function of myeloid cells, we hypothesized that CHIP may also be associated with the risk of Alzheimer's disease (AD), a disease in which brain-resident myeloid cells are thought to have a major role. To perform association tests between CHIP and AD dementia, we analyzed blood DNA sequencing data from 1,362...]]></summary>
        <author>
            <name>Hind Bouzid</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is associated with protection from Alzheimer's disease]]></title>
        <id>pubmed:37322115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37322115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a premalignant expansion of mutated hematopoietic stem cells. As CHIP-associated mutations are known to alter the development and function of myeloid cells, we hypothesized that CHIP may also be associated with the risk of Alzheimer's disease (AD), a disease in which brain-resident myeloid cells are thought to have a major role. To perform association tests between CHIP and AD dementia, we analyzed blood DNA sequencing data from 1,362...]]></summary>
        <author>
            <name>Hind Bouzid</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is associated with protection from Alzheimer's disease]]></title>
        <id>pubmed:37322115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37322115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a premalignant expansion of mutated hematopoietic stem cells. As CHIP-associated mutations are known to alter the development and function of myeloid cells, we hypothesized that CHIP may also be associated with the risk of Alzheimer's disease (AD), a disease in which brain-resident myeloid cells are thought to have a major role. To perform association tests between CHIP and AD dementia, we analyzed blood DNA sequencing data from 1,362...]]></summary>
        <author>
            <name>Hind Bouzid</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is associated with protection from Alzheimer's disease]]></title>
        <id>pubmed:37322115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37322115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a premalignant expansion of mutated hematopoietic stem cells. As CHIP-associated mutations are known to alter the development and function of myeloid cells, we hypothesized that CHIP may also be associated with the risk of Alzheimer's disease (AD), a disease in which brain-resident myeloid cells are thought to have a major role. To perform association tests between CHIP and AD dementia, we analyzed blood DNA sequencing data from 1,362...]]></summary>
        <author>
            <name>Hind Bouzid</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis is associated with protection from Alzheimer's disease]]></title>
        <id>pubmed:37322115</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37322115/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is a premalignant expansion of mutated hematopoietic stem cells. As CHIP-associated mutations are known to alter the development and function of myeloid cells, we hypothesized that CHIP may also be associated with the risk of Alzheimer's disease (AD), a disease in which brain-resident myeloid cells are thought to have a major role. To perform association tests between CHIP and AD dementia, we analyzed blood DNA sequencing data from 1,362...]]></summary>
        <author>
            <name>Hind Bouzid</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)]]></title>
        <id>pubmed:37316755</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37316755/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are incurable diseases characterized by dysplastic hematopoietic cells, cytopenias in the blood and an inherent tendency for transformation to secondary acute myeloid leukemia (AML). Since most therapies fail to prevent rapid clonal evolution and disease resistance, new and non-invasive predictive markers are needed to monitor patients and adapt the therapeutic strategy. By using ISET, a very sensitive approach to isolate cells larger than mature leukocytes from...]]></summary>
        <author>
            <name>Abdullah Mahmood Ali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)]]></title>
        <id>pubmed:37316755</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37316755/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are incurable diseases characterized by dysplastic hematopoietic cells, cytopenias in the blood and an inherent tendency for transformation to secondary acute myeloid leukemia (AML). Since most therapies fail to prevent rapid clonal evolution and disease resistance, new and non-invasive predictive markers are needed to monitor patients and adapt the therapeutic strategy. By using ISET, a very sensitive approach to isolate cells larger than mature leukocytes from...]]></summary>
        <author>
            <name>Abdullah Mahmood Ali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)]]></title>
        <id>pubmed:37316755</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37316755/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are incurable diseases characterized by dysplastic hematopoietic cells, cytopenias in the blood and an inherent tendency for transformation to secondary acute myeloid leukemia (AML). Since most therapies fail to prevent rapid clonal evolution and disease resistance, new and non-invasive predictive markers are needed to monitor patients and adapt the therapeutic strategy. By using ISET, a very sensitive approach to isolate cells larger than mature leukocytes from...]]></summary>
        <author>
            <name>Abdullah Mahmood Ali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)]]></title>
        <id>pubmed:37316755</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37316755/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are incurable diseases characterized by dysplastic hematopoietic cells, cytopenias in the blood and an inherent tendency for transformation to secondary acute myeloid leukemia (AML). Since most therapies fail to prevent rapid clonal evolution and disease resistance, new and non-invasive predictive markers are needed to monitor patients and adapt the therapeutic strategy. By using ISET, a very sensitive approach to isolate cells larger than mature leukocytes from...]]></summary>
        <author>
            <name>Abdullah Mahmood Ali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)]]></title>
        <id>pubmed:37316755</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37316755/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are incurable diseases characterized by dysplastic hematopoietic cells, cytopenias in the blood and an inherent tendency for transformation to secondary acute myeloid leukemia (AML). Since most therapies fail to prevent rapid clonal evolution and disease resistance, new and non-invasive predictive markers are needed to monitor patients and adapt the therapeutic strategy. By using ISET, a very sensitive approach to isolate cells larger than mature leukocytes from...]]></summary>
        <author>
            <name>Abdullah Mahmood Ali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)]]></title>
        <id>pubmed:37316755</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37316755/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are incurable diseases characterized by dysplastic hematopoietic cells, cytopenias in the blood and an inherent tendency for transformation to secondary acute myeloid leukemia (AML). Since most therapies fail to prevent rapid clonal evolution and disease resistance, new and non-invasive predictive markers are needed to monitor patients and adapt the therapeutic strategy. By using ISET, a very sensitive approach to isolate cells larger than mature leukocytes from...]]></summary>
        <author>
            <name>Abdullah Mahmood Ali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)]]></title>
        <id>pubmed:37316755</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37316755/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are incurable diseases characterized by dysplastic hematopoietic cells, cytopenias in the blood and an inherent tendency for transformation to secondary acute myeloid leukemia (AML). Since most therapies fail to prevent rapid clonal evolution and disease resistance, new and non-invasive predictive markers are needed to monitor patients and adapt the therapeutic strategy. By using ISET, a very sensitive approach to isolate cells larger than mature leukocytes from...]]></summary>
        <author>
            <name>Abdullah Mahmood Ali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)]]></title>
        <id>pubmed:37316755</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37316755/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are incurable diseases characterized by dysplastic hematopoietic cells, cytopenias in the blood and an inherent tendency for transformation to secondary acute myeloid leukemia (AML). Since most therapies fail to prevent rapid clonal evolution and disease resistance, new and non-invasive predictive markers are needed to monitor patients and adapt the therapeutic strategy. By using ISET, a very sensitive approach to isolate cells larger than mature leukocytes from...]]></summary>
        <author>
            <name>Abdullah Mahmood Ali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)]]></title>
        <id>pubmed:37316755</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37316755/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are incurable diseases characterized by dysplastic hematopoietic cells, cytopenias in the blood and an inherent tendency for transformation to secondary acute myeloid leukemia (AML). Since most therapies fail to prevent rapid clonal evolution and disease resistance, new and non-invasive predictive markers are needed to monitor patients and adapt the therapeutic strategy. By using ISET, a very sensitive approach to isolate cells larger than mature leukocytes from...]]></summary>
        <author>
            <name>Abdullah Mahmood Ali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)]]></title>
        <id>pubmed:37316755</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37316755/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are incurable diseases characterized by dysplastic hematopoietic cells, cytopenias in the blood and an inherent tendency for transformation to secondary acute myeloid leukemia (AML). Since most therapies fail to prevent rapid clonal evolution and disease resistance, new and non-invasive predictive markers are needed to monitor patients and adapt the therapeutic strategy. By using ISET, a very sensitive approach to isolate cells larger than mature leukocytes from...]]></summary>
        <author>
            <name>Abdullah Mahmood Ali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)]]></title>
        <id>pubmed:37316755</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37316755/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are incurable diseases characterized by dysplastic hematopoietic cells, cytopenias in the blood and an inherent tendency for transformation to secondary acute myeloid leukemia (AML). Since most therapies fail to prevent rapid clonal evolution and disease resistance, new and non-invasive predictive markers are needed to monitor patients and adapt the therapeutic strategy. By using ISET, a very sensitive approach to isolate cells larger than mature leukocytes from...]]></summary>
        <author>
            <name>Abdullah Mahmood Ali</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease]]></title>
        <id>pubmed:37311413</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37311413/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma remains an incurable disease, and the cellular and molecular evolution from precursor conditions, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, is incompletely understood. Here, we combine single-cell RNA and B cell receptor sequencing from fifty-two patients with myeloma precursors in comparison with myeloma and normal donors. Our comprehensive analysis reveals early genomic drivers of malignant transformation, distinct...]]></summary>
        <author>
            <name>Minghao Dang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease]]></title>
        <id>pubmed:37311413</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37311413/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma remains an incurable disease, and the cellular and molecular evolution from precursor conditions, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, is incompletely understood. Here, we combine single-cell RNA and B cell receptor sequencing from fifty-two patients with myeloma precursors in comparison with myeloma and normal donors. Our comprehensive analysis reveals early genomic drivers of malignant transformation, distinct...]]></summary>
        <author>
            <name>Minghao Dang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells]]></title>
        <id>pubmed:37310508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37310508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer endocrine therapy can promote evolutionary dynamics and lead to changes in the gene expression profile of tumor cells. We aimed to assess the effect of tamoxifen (TAM)-resistance induction on ABCG2 pump mRNA, protein, and activity in ER + MCF-7 breast cancer cells. We also evaluated if the resistance to TAM leads to the cross-resistance toward mitoxantrone (MX), a well-known substrate of the ABCG2 pump. The ABCG2 mRNA and protein expression were compared in MCF-7 and its TAM-resistant...]]></summary>
        <author>
            <name>Asefeh Dahmardeh Ghalehno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease]]></title>
        <id>pubmed:37311413</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37311413/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma remains an incurable disease, and the cellular and molecular evolution from precursor conditions, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, is incompletely understood. Here, we combine single-cell RNA and B cell receptor sequencing from fifty-two patients with myeloma precursors in comparison with myeloma and normal donors. Our comprehensive analysis reveals early genomic drivers of malignant transformation, distinct...]]></summary>
        <author>
            <name>Minghao Dang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells]]></title>
        <id>pubmed:37310508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37310508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer endocrine therapy can promote evolutionary dynamics and lead to changes in the gene expression profile of tumor cells. We aimed to assess the effect of tamoxifen (TAM)-resistance induction on ABCG2 pump mRNA, protein, and activity in ER + MCF-7 breast cancer cells. We also evaluated if the resistance to TAM leads to the cross-resistance toward mitoxantrone (MX), a well-known substrate of the ABCG2 pump. The ABCG2 mRNA and protein expression were compared in MCF-7 and its TAM-resistant...]]></summary>
        <author>
            <name>Asefeh Dahmardeh Ghalehno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease]]></title>
        <id>pubmed:37311413</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37311413/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma remains an incurable disease, and the cellular and molecular evolution from precursor conditions, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, is incompletely understood. Here, we combine single-cell RNA and B cell receptor sequencing from fifty-two patients with myeloma precursors in comparison with myeloma and normal donors. Our comprehensive analysis reveals early genomic drivers of malignant transformation, distinct...]]></summary>
        <author>
            <name>Minghao Dang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells]]></title>
        <id>pubmed:37310508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37310508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer endocrine therapy can promote evolutionary dynamics and lead to changes in the gene expression profile of tumor cells. We aimed to assess the effect of tamoxifen (TAM)-resistance induction on ABCG2 pump mRNA, protein, and activity in ER + MCF-7 breast cancer cells. We also evaluated if the resistance to TAM leads to the cross-resistance toward mitoxantrone (MX), a well-known substrate of the ABCG2 pump. The ABCG2 mRNA and protein expression were compared in MCF-7 and its TAM-resistant...]]></summary>
        <author>
            <name>Asefeh Dahmardeh Ghalehno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease]]></title>
        <id>pubmed:37311413</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37311413/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma remains an incurable disease, and the cellular and molecular evolution from precursor conditions, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, is incompletely understood. Here, we combine single-cell RNA and B cell receptor sequencing from fifty-two patients with myeloma precursors in comparison with myeloma and normal donors. Our comprehensive analysis reveals early genomic drivers of malignant transformation, distinct...]]></summary>
        <author>
            <name>Minghao Dang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells]]></title>
        <id>pubmed:37310508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37310508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer endocrine therapy can promote evolutionary dynamics and lead to changes in the gene expression profile of tumor cells. We aimed to assess the effect of tamoxifen (TAM)-resistance induction on ABCG2 pump mRNA, protein, and activity in ER + MCF-7 breast cancer cells. We also evaluated if the resistance to TAM leads to the cross-resistance toward mitoxantrone (MX), a well-known substrate of the ABCG2 pump. The ABCG2 mRNA and protein expression were compared in MCF-7 and its TAM-resistant...]]></summary>
        <author>
            <name>Asefeh Dahmardeh Ghalehno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease]]></title>
        <id>pubmed:37311413</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37311413/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma remains an incurable disease, and the cellular and molecular evolution from precursor conditions, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, is incompletely understood. Here, we combine single-cell RNA and B cell receptor sequencing from fifty-two patients with myeloma precursors in comparison with myeloma and normal donors. Our comprehensive analysis reveals early genomic drivers of malignant transformation, distinct...]]></summary>
        <author>
            <name>Minghao Dang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells]]></title>
        <id>pubmed:37310508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37310508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer endocrine therapy can promote evolutionary dynamics and lead to changes in the gene expression profile of tumor cells. We aimed to assess the effect of tamoxifen (TAM)-resistance induction on ABCG2 pump mRNA, protein, and activity in ER + MCF-7 breast cancer cells. We also evaluated if the resistance to TAM leads to the cross-resistance toward mitoxantrone (MX), a well-known substrate of the ABCG2 pump. The ABCG2 mRNA and protein expression were compared in MCF-7 and its TAM-resistant...]]></summary>
        <author>
            <name>Asefeh Dahmardeh Ghalehno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease]]></title>
        <id>pubmed:37311413</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37311413/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma remains an incurable disease, and the cellular and molecular evolution from precursor conditions, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, is incompletely understood. Here, we combine single-cell RNA and B cell receptor sequencing from fifty-two patients with myeloma precursors in comparison with myeloma and normal donors. Our comprehensive analysis reveals early genomic drivers of malignant transformation, distinct...]]></summary>
        <author>
            <name>Minghao Dang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells]]></title>
        <id>pubmed:37310508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37310508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer endocrine therapy can promote evolutionary dynamics and lead to changes in the gene expression profile of tumor cells. We aimed to assess the effect of tamoxifen (TAM)-resistance induction on ABCG2 pump mRNA, protein, and activity in ER + MCF-7 breast cancer cells. We also evaluated if the resistance to TAM leads to the cross-resistance toward mitoxantrone (MX), a well-known substrate of the ABCG2 pump. The ABCG2 mRNA and protein expression were compared in MCF-7 and its TAM-resistant...]]></summary>
        <author>
            <name>Asefeh Dahmardeh Ghalehno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease]]></title>
        <id>pubmed:37311413</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37311413/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma remains an incurable disease, and the cellular and molecular evolution from precursor conditions, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, is incompletely understood. Here, we combine single-cell RNA and B cell receptor sequencing from fifty-two patients with myeloma precursors in comparison with myeloma and normal donors. Our comprehensive analysis reveals early genomic drivers of malignant transformation, distinct...]]></summary>
        <author>
            <name>Minghao Dang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells]]></title>
        <id>pubmed:37310508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37310508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer endocrine therapy can promote evolutionary dynamics and lead to changes in the gene expression profile of tumor cells. We aimed to assess the effect of tamoxifen (TAM)-resistance induction on ABCG2 pump mRNA, protein, and activity in ER + MCF-7 breast cancer cells. We also evaluated if the resistance to TAM leads to the cross-resistance toward mitoxantrone (MX), a well-known substrate of the ABCG2 pump. The ABCG2 mRNA and protein expression were compared in MCF-7 and its TAM-resistant...]]></summary>
        <author>
            <name>Asefeh Dahmardeh Ghalehno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease]]></title>
        <id>pubmed:37311413</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37311413/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma remains an incurable disease, and the cellular and molecular evolution from precursor conditions, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, is incompletely understood. Here, we combine single-cell RNA and B cell receptor sequencing from fifty-two patients with myeloma precursors in comparison with myeloma and normal donors. Our comprehensive analysis reveals early genomic drivers of malignant transformation, distinct...]]></summary>
        <author>
            <name>Minghao Dang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells]]></title>
        <id>pubmed:37310508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37310508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer endocrine therapy can promote evolutionary dynamics and lead to changes in the gene expression profile of tumor cells. We aimed to assess the effect of tamoxifen (TAM)-resistance induction on ABCG2 pump mRNA, protein, and activity in ER + MCF-7 breast cancer cells. We also evaluated if the resistance to TAM leads to the cross-resistance toward mitoxantrone (MX), a well-known substrate of the ABCG2 pump. The ABCG2 mRNA and protein expression were compared in MCF-7 and its TAM-resistant...]]></summary>
        <author>
            <name>Asefeh Dahmardeh Ghalehno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease]]></title>
        <id>pubmed:37311413</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37311413/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma remains an incurable disease, and the cellular and molecular evolution from precursor conditions, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, is incompletely understood. Here, we combine single-cell RNA and B cell receptor sequencing from fifty-two patients with myeloma precursors in comparison with myeloma and normal donors. Our comprehensive analysis reveals early genomic drivers of malignant transformation, distinct...]]></summary>
        <author>
            <name>Minghao Dang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells]]></title>
        <id>pubmed:37310508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37310508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer endocrine therapy can promote evolutionary dynamics and lead to changes in the gene expression profile of tumor cells. We aimed to assess the effect of tamoxifen (TAM)-resistance induction on ABCG2 pump mRNA, protein, and activity in ER + MCF-7 breast cancer cells. We also evaluated if the resistance to TAM leads to the cross-resistance toward mitoxantrone (MX), a well-known substrate of the ABCG2 pump. The ABCG2 mRNA and protein expression were compared in MCF-7 and its TAM-resistant...]]></summary>
        <author>
            <name>Asefeh Dahmardeh Ghalehno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease]]></title>
        <id>pubmed:37311413</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37311413/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma remains an incurable disease, and the cellular and molecular evolution from precursor conditions, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, is incompletely understood. Here, we combine single-cell RNA and B cell receptor sequencing from fifty-two patients with myeloma precursors in comparison with myeloma and normal donors. Our comprehensive analysis reveals early genomic drivers of malignant transformation, distinct...]]></summary>
        <author>
            <name>Minghao Dang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells]]></title>
        <id>pubmed:37310508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37310508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer endocrine therapy can promote evolutionary dynamics and lead to changes in the gene expression profile of tumor cells. We aimed to assess the effect of tamoxifen (TAM)-resistance induction on ABCG2 pump mRNA, protein, and activity in ER + MCF-7 breast cancer cells. We also evaluated if the resistance to TAM leads to the cross-resistance toward mitoxantrone (MX), a well-known substrate of the ABCG2 pump. The ABCG2 mRNA and protein expression were compared in MCF-7 and its TAM-resistant...]]></summary>
        <author>
            <name>Asefeh Dahmardeh Ghalehno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease]]></title>
        <id>pubmed:37311413</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37311413/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma remains an incurable disease, and the cellular and molecular evolution from precursor conditions, including monoclonal gammopathy of undetermined significance and smoldering multiple myeloma, is incompletely understood. Here, we combine single-cell RNA and B cell receptor sequencing from fifty-two patients with myeloma precursors in comparison with myeloma and normal donors. Our comprehensive analysis reveals early genomic drivers of malignant transformation, distinct...]]></summary>
        <author>
            <name>Minghao Dang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells]]></title>
        <id>pubmed:37310508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37310508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer endocrine therapy can promote evolutionary dynamics and lead to changes in the gene expression profile of tumor cells. We aimed to assess the effect of tamoxifen (TAM)-resistance induction on ABCG2 pump mRNA, protein, and activity in ER + MCF-7 breast cancer cells. We also evaluated if the resistance to TAM leads to the cross-resistance toward mitoxantrone (MX), a well-known substrate of the ABCG2 pump. The ABCG2 mRNA and protein expression were compared in MCF-7 and its TAM-resistant...]]></summary>
        <author>
            <name>Asefeh Dahmardeh Ghalehno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells]]></title>
        <id>pubmed:37310508</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37310508/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer endocrine therapy can promote evolutionary dynamics and lead to changes in the gene expression profile of tumor cells. We aimed to assess the effect of tamoxifen (TAM)-resistance induction on ABCG2 pump mRNA, protein, and activity in ER + MCF-7 breast cancer cells. We also evaluated if the resistance to TAM leads to the cross-resistance toward mitoxantrone (MX), a well-known substrate of the ABCG2 pump. The ABCG2 mRNA and protein expression were compared in MCF-7 and its TAM-resistant...]]></summary>
        <author>
            <name>Asefeh Dahmardeh Ghalehno</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution and hierarchy in myeloid malignancies]]></title>
        <id>pubmed:37302922</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37302922/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloid malignancies, a group of hematopoietic disorders that includes acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs), are caused by the accumulation of genetic and epigenetic changes in hematopoietic stem and progenitor cells (HSPCs) over time. Despite the relatively low number of genomic drivers compared with other forms of cancer, the process by which these changes shape the genomic architecture of myeloid malignancies remains elusive....]]></summary>
        <author>
            <name>Koichi Takahashi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential is Associated with Acute Kidney Injury]]></title>
        <id>pubmed:37292692</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292692/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age is a predominant risk factor for acute kidney injury (AKI), yet the biological mechanisms underlying this risk are largely unknown and to date no genetic mechanisms for AKI have been established. Clonal hematopoiesis of indeterminate potential (CHIP) is a recently recognized biological mechanism conferring risk of several chronic aging diseases including cardiovascular disease, pulmonary disease and liver disease. In CHIP, blood stem cells acquire mutations in myeloid cancer driver genes...]]></summary>
        <author>
            <name>Caitlyn Vlasschaert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution]]></title>
        <id>pubmed:37292686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity underlies cancer evolution and treatment resistance ^(1-5) , but targetable mechanisms driving intratumor heterogeneity are poorly understood. Meningiomas are the most common primary intracranial tumors and are resistant to all current medical therapies ^(6,7) . High-grade meningiomas cause significant neurological morbidity and mortality and are distinguished from low-grade meningiomas by increased intratumor heterogeneity arising from clonal evolution and divergence ⁸...]]></summary>
        <author>
            <name>Calixto-Hope Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution]]></title>
        <id>pubmed:37292686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity underlies cancer evolution and treatment resistance ^(1-5) , but targetable mechanisms driving intratumor heterogeneity are poorly understood. Meningiomas are the most common primary intracranial tumors and are resistant to all current medical therapies ^(6,7) . High-grade meningiomas cause significant neurological morbidity and mortality and are distinguished from low-grade meningiomas by increased intratumor heterogeneity arising from clonal evolution and divergence ⁸...]]></summary>
        <author>
            <name>Calixto-Hope Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution]]></title>
        <id>pubmed:37292686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity underlies cancer evolution and treatment resistance ^(1-5) , but targetable mechanisms driving intratumor heterogeneity are poorly understood. Meningiomas are the most common primary intracranial tumors and are resistant to all current medical therapies ^(6,7) . High-grade meningiomas cause significant neurological morbidity and mortality and are distinguished from low-grade meningiomas by increased intratumor heterogeneity arising from clonal evolution and divergence ⁸...]]></summary>
        <author>
            <name>Calixto-Hope Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution]]></title>
        <id>pubmed:37292686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity underlies cancer evolution and treatment resistance ^(1-5) , but targetable mechanisms driving intratumor heterogeneity are poorly understood. Meningiomas are the most common primary intracranial tumors and are resistant to all current medical therapies ^(6,7) . High-grade meningiomas cause significant neurological morbidity and mortality and are distinguished from low-grade meningiomas by increased intratumor heterogeneity arising from clonal evolution and divergence ⁸...]]></summary>
        <author>
            <name>Calixto-Hope Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution]]></title>
        <id>pubmed:37292686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity underlies cancer evolution and treatment resistance ^(1-5) , but targetable mechanisms driving intratumor heterogeneity are poorly understood. Meningiomas are the most common primary intracranial tumors and are resistant to all current medical therapies ^(6,7) . High-grade meningiomas cause significant neurological morbidity and mortality and are distinguished from low-grade meningiomas by increased intratumor heterogeneity arising from clonal evolution and divergence ⁸...]]></summary>
        <author>
            <name>Calixto-Hope Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution]]></title>
        <id>pubmed:37292686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity underlies cancer evolution and treatment resistance ^(1-5) , but targetable mechanisms driving intratumor heterogeneity are poorly understood. Meningiomas are the most common primary intracranial tumors and are resistant to all current medical therapies ^(6,7) . High-grade meningiomas cause significant neurological morbidity and mortality and are distinguished from low-grade meningiomas by increased intratumor heterogeneity arising from clonal evolution and divergence ⁸...]]></summary>
        <author>
            <name>Calixto-Hope Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution]]></title>
        <id>pubmed:37292686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity underlies cancer evolution and treatment resistance ^(1-5) , but targetable mechanisms driving intratumor heterogeneity are poorly understood. Meningiomas are the most common primary intracranial tumors and are resistant to all current medical therapies ^(6,7) . High-grade meningiomas cause significant neurological morbidity and mortality and are distinguished from low-grade meningiomas by increased intratumor heterogeneity arising from clonal evolution and divergence ⁸...]]></summary>
        <author>
            <name>Calixto-Hope Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution]]></title>
        <id>pubmed:37292686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity underlies cancer evolution and treatment resistance ^(1-5) , but targetable mechanisms driving intratumor heterogeneity are poorly understood. Meningiomas are the most common primary intracranial tumors and are resistant to all current medical therapies ^(6,7) . High-grade meningiomas cause significant neurological morbidity and mortality and are distinguished from low-grade meningiomas by increased intratumor heterogeneity arising from clonal evolution and divergence ⁸...]]></summary>
        <author>
            <name>Calixto-Hope Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution]]></title>
        <id>pubmed:37292686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity underlies cancer evolution and treatment resistance ^(1-5) , but targetable mechanisms driving intratumor heterogeneity are poorly understood. Meningiomas are the most common primary intracranial tumors and are resistant to all current medical therapies ^(6,7) . High-grade meningiomas cause significant neurological morbidity and mortality and are distinguished from low-grade meningiomas by increased intratumor heterogeneity arising from clonal evolution and divergence ⁸...]]></summary>
        <author>
            <name>Calixto-Hope Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution]]></title>
        <id>pubmed:37292686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity underlies cancer evolution and treatment resistance ^(1-5) , but targetable mechanisms driving intratumor heterogeneity are poorly understood. Meningiomas are the most common primary intracranial tumors and are resistant to all current medical therapies ^(6,7) . High-grade meningiomas cause significant neurological morbidity and mortality and are distinguished from low-grade meningiomas by increased intratumor heterogeneity arising from clonal evolution and divergence ⁸...]]></summary>
        <author>
            <name>Calixto-Hope Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution]]></title>
        <id>pubmed:37292686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity underlies cancer evolution and treatment resistance ^(1-5) , but targetable mechanisms driving intratumor heterogeneity are poorly understood. Meningiomas are the most common primary intracranial tumors and are resistant to all current medical therapies ^(6,7) . High-grade meningiomas cause significant neurological morbidity and mortality and are distinguished from low-grade meningiomas by increased intratumor heterogeneity arising from clonal evolution and divergence ⁸...]]></summary>
        <author>
            <name>Calixto-Hope Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution]]></title>
        <id>pubmed:37292686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity underlies cancer evolution and treatment resistance ^(1-5) , but targetable mechanisms driving intratumor heterogeneity are poorly understood. Meningiomas are the most common primary intracranial tumors and are resistant to all current medical therapies ^(6,7) . High-grade meningiomas cause significant neurological morbidity and mortality and are distinguished from low-grade meningiomas by increased intratumor heterogeneity arising from clonal evolution and divergence ⁸...]]></summary>
        <author>
            <name>Calixto-Hope Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution]]></title>
        <id>pubmed:37292686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity underlies cancer evolution and treatment resistance ^(1-5) , but targetable mechanisms driving intratumor heterogeneity are poorly understood. Meningiomas are the most common primary intracranial tumors and are resistant to all current medical therapies ^(6,7) . High-grade meningiomas cause significant neurological morbidity and mortality and are distinguished from low-grade meningiomas by increased intratumor heterogeneity arising from clonal evolution and divergence ⁸...]]></summary>
        <author>
            <name>Calixto-Hope Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial genomic, biochemical, and cellular mechanisms drive meningioma heterogeneity and evolution]]></title>
        <id>pubmed:37292686</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37292686/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity underlies cancer evolution and treatment resistance ^(1-5) , but targetable mechanisms driving intratumor heterogeneity are poorly understood. Meningiomas are the most common primary intracranial tumors and are resistant to all current medical therapies ^(6,7) . High-grade meningiomas cause significant neurological morbidity and mortality and are distinguished from low-grade meningiomas by increased intratumor heterogeneity arising from clonal evolution and divergence ⁸...]]></summary>
        <author>
            <name>Calixto-Hope Lucas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230626211237&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The coming of age of liquid biopsy in neuro-oncology]]></title>
        <id>pubmed:37289981</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37289981/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other brain tumors, targeted sequencing of cell-free DNA (cfDNA) from cerebrospinal fluid (CSF) may help differential diagnosis when surgery is not recommended and be more representative of tumor heterogeneity than surgical specimens, unveiling targetable genetic alterations. Given the invasive nature of lumbar puncture to obtain CSF, the quantitative analysis of cfDNA in plasma is a lively option for patient...]]></summary>
        <author>
            <name>Giulia Berzero</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Heritable transcriptional defects from aberrations of nuclear architecture]]></title>
        <id>pubmed:37286600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transcriptional heterogeneity due to plasticity of the epigenetic state of chromatin contributes to tumour evolution, metastasis and drug resistance^(1-3). However, the mechanisms that cause this epigenetic variation are incompletely understood. Here we identify micronuclei and chromosome bridges, aberrations in the nucleus common in cancer^(4,5), as sources of heritable transcriptional suppression. Using a combination of approaches, including long-term live-cell imaging and same-cell...]]></summary>
        <author>
            <name>Stamatis Papathanasiou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Heritable transcriptional defects from aberrations of nuclear architecture]]></title>
        <id>pubmed:37286600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transcriptional heterogeneity due to plasticity of the epigenetic state of chromatin contributes to tumour evolution, metastasis and drug resistance^(1-3). However, the mechanisms that cause this epigenetic variation are incompletely understood. Here we identify micronuclei and chromosome bridges, aberrations in the nucleus common in cancer^(4,5), as sources of heritable transcriptional suppression. Using a combination of approaches, including long-term live-cell imaging and same-cell...]]></summary>
        <author>
            <name>Stamatis Papathanasiou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin]]></title>
        <id>pubmed:37286599</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286599/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumours most often arise from progression of precursor clones within a single anatomical niche. In the bone marrow, clonal progenitors can undergo malignant transformation to acute leukaemia, or differentiate into immune cells that contribute to disease pathology in peripheral tissues^(1-4). Outside the marrow, these clones are potentially exposed to a variety of tissue-specific mutational processes, although the consequences of this are unclear. Here we investigate the development of blastic...]]></summary>
        <author>
            <name>Gabriel K Griffin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[gUMI-BEAR, a modular, unsupervised population barcoding method to track variants and evolution at high resolution]]></title>
        <id>pubmed:37285353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage tracking provides a means to observe population makeup at the clonal level, allowing exploration of heterogeneity, evolutionary and developmental processes and individual clones' relative fitness. It has thus contributed significantly to understanding microbial evolution, organ differentiation and cancer heterogeneity, among others. Its use, however, is limited because existing methods are highly specific, expensive, labour-intensive, and, critically, do not allow the repetition...]]></summary>
        <author>
            <name>Shahar Rezenman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Heritable transcriptional defects from aberrations of nuclear architecture]]></title>
        <id>pubmed:37286600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transcriptional heterogeneity due to plasticity of the epigenetic state of chromatin contributes to tumour evolution, metastasis and drug resistance^(1-3). However, the mechanisms that cause this epigenetic variation are incompletely understood. Here we identify micronuclei and chromosome bridges, aberrations in the nucleus common in cancer^(4,5), as sources of heritable transcriptional suppression. Using a combination of approaches, including long-term live-cell imaging and same-cell...]]></summary>
        <author>
            <name>Stamatis Papathanasiou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin]]></title>
        <id>pubmed:37286599</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286599/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumours most often arise from progression of precursor clones within a single anatomical niche. In the bone marrow, clonal progenitors can undergo malignant transformation to acute leukaemia, or differentiate into immune cells that contribute to disease pathology in peripheral tissues^(1-4). Outside the marrow, these clones are potentially exposed to a variety of tissue-specific mutational processes, although the consequences of this are unclear. Here we investigate the development of blastic...]]></summary>
        <author>
            <name>Gabriel K Griffin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[gUMI-BEAR, a modular, unsupervised population barcoding method to track variants and evolution at high resolution]]></title>
        <id>pubmed:37285353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage tracking provides a means to observe population makeup at the clonal level, allowing exploration of heterogeneity, evolutionary and developmental processes and individual clones' relative fitness. It has thus contributed significantly to understanding microbial evolution, organ differentiation and cancer heterogeneity, among others. Its use, however, is limited because existing methods are highly specific, expensive, labour-intensive, and, critically, do not allow the repetition...]]></summary>
        <author>
            <name>Shahar Rezenman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins]]></title>
        <id>pubmed:37285266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remain unclear. We conduct whole-exome and multiregional sequencing on 101 samples from 33 patients to elucidate their evolutionary paths. We identify four significantly mutated genes, TP53, RB1, APC, and CTNNB1. MANEC resembles chromosomal instability stomach...]]></summary>
        <author>
            <name>Miao-Zhen Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Heritable transcriptional defects from aberrations of nuclear architecture]]></title>
        <id>pubmed:37286600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transcriptional heterogeneity due to plasticity of the epigenetic state of chromatin contributes to tumour evolution, metastasis and drug resistance^(1-3). However, the mechanisms that cause this epigenetic variation are incompletely understood. Here we identify micronuclei and chromosome bridges, aberrations in the nucleus common in cancer^(4,5), as sources of heritable transcriptional suppression. Using a combination of approaches, including long-term live-cell imaging and same-cell...]]></summary>
        <author>
            <name>Stamatis Papathanasiou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin]]></title>
        <id>pubmed:37286599</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286599/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumours most often arise from progression of precursor clones within a single anatomical niche. In the bone marrow, clonal progenitors can undergo malignant transformation to acute leukaemia, or differentiate into immune cells that contribute to disease pathology in peripheral tissues^(1-4). Outside the marrow, these clones are potentially exposed to a variety of tissue-specific mutational processes, although the consequences of this are unclear. Here we investigate the development of blastic...]]></summary>
        <author>
            <name>Gabriel K Griffin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[gUMI-BEAR, a modular, unsupervised population barcoding method to track variants and evolution at high resolution]]></title>
        <id>pubmed:37285353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage tracking provides a means to observe population makeup at the clonal level, allowing exploration of heterogeneity, evolutionary and developmental processes and individual clones' relative fitness. It has thus contributed significantly to understanding microbial evolution, organ differentiation and cancer heterogeneity, among others. Its use, however, is limited because existing methods are highly specific, expensive, labour-intensive, and, critically, do not allow the repetition...]]></summary>
        <author>
            <name>Shahar Rezenman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins]]></title>
        <id>pubmed:37285266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remain unclear. We conduct whole-exome and multiregional sequencing on 101 samples from 33 patients to elucidate their evolutionary paths. We identify four significantly mutated genes, TP53, RB1, APC, and CTNNB1. MANEC resembles chromosomal instability stomach...]]></summary>
        <author>
            <name>Miao-Zhen Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Heritable transcriptional defects from aberrations of nuclear architecture]]></title>
        <id>pubmed:37286600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transcriptional heterogeneity due to plasticity of the epigenetic state of chromatin contributes to tumour evolution, metastasis and drug resistance^(1-3). However, the mechanisms that cause this epigenetic variation are incompletely understood. Here we identify micronuclei and chromosome bridges, aberrations in the nucleus common in cancer^(4,5), as sources of heritable transcriptional suppression. Using a combination of approaches, including long-term live-cell imaging and same-cell...]]></summary>
        <author>
            <name>Stamatis Papathanasiou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin]]></title>
        <id>pubmed:37286599</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286599/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumours most often arise from progression of precursor clones within a single anatomical niche. In the bone marrow, clonal progenitors can undergo malignant transformation to acute leukaemia, or differentiate into immune cells that contribute to disease pathology in peripheral tissues^(1-4). Outside the marrow, these clones are potentially exposed to a variety of tissue-specific mutational processes, although the consequences of this are unclear. Here we investigate the development of blastic...]]></summary>
        <author>
            <name>Gabriel K Griffin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[gUMI-BEAR, a modular, unsupervised population barcoding method to track variants and evolution at high resolution]]></title>
        <id>pubmed:37285353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage tracking provides a means to observe population makeup at the clonal level, allowing exploration of heterogeneity, evolutionary and developmental processes and individual clones' relative fitness. It has thus contributed significantly to understanding microbial evolution, organ differentiation and cancer heterogeneity, among others. Its use, however, is limited because existing methods are highly specific, expensive, labour-intensive, and, critically, do not allow the repetition...]]></summary>
        <author>
            <name>Shahar Rezenman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins]]></title>
        <id>pubmed:37285266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remain unclear. We conduct whole-exome and multiregional sequencing on 101 samples from 33 patients to elucidate their evolutionary paths. We identify four significantly mutated genes, TP53, RB1, APC, and CTNNB1. MANEC resembles chromosomal instability stomach...]]></summary>
        <author>
            <name>Miao-Zhen Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Heritable transcriptional defects from aberrations of nuclear architecture]]></title>
        <id>pubmed:37286600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transcriptional heterogeneity due to plasticity of the epigenetic state of chromatin contributes to tumour evolution, metastasis and drug resistance^(1-3). However, the mechanisms that cause this epigenetic variation are incompletely understood. Here we identify micronuclei and chromosome bridges, aberrations in the nucleus common in cancer^(4,5), as sources of heritable transcriptional suppression. Using a combination of approaches, including long-term live-cell imaging and same-cell...]]></summary>
        <author>
            <name>Stamatis Papathanasiou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin]]></title>
        <id>pubmed:37286599</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286599/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumours most often arise from progression of precursor clones within a single anatomical niche. In the bone marrow, clonal progenitors can undergo malignant transformation to acute leukaemia, or differentiate into immune cells that contribute to disease pathology in peripheral tissues^(1-4). Outside the marrow, these clones are potentially exposed to a variety of tissue-specific mutational processes, although the consequences of this are unclear. Here we investigate the development of blastic...]]></summary>
        <author>
            <name>Gabriel K Griffin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[gUMI-BEAR, a modular, unsupervised population barcoding method to track variants and evolution at high resolution]]></title>
        <id>pubmed:37285353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage tracking provides a means to observe population makeup at the clonal level, allowing exploration of heterogeneity, evolutionary and developmental processes and individual clones' relative fitness. It has thus contributed significantly to understanding microbial evolution, organ differentiation and cancer heterogeneity, among others. Its use, however, is limited because existing methods are highly specific, expensive, labour-intensive, and, critically, do not allow the repetition...]]></summary>
        <author>
            <name>Shahar Rezenman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins]]></title>
        <id>pubmed:37285266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remain unclear. We conduct whole-exome and multiregional sequencing on 101 samples from 33 patients to elucidate their evolutionary paths. We identify four significantly mutated genes, TP53, RB1, APC, and CTNNB1. MANEC resembles chromosomal instability stomach...]]></summary>
        <author>
            <name>Miao-Zhen Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Heritable transcriptional defects from aberrations of nuclear architecture]]></title>
        <id>pubmed:37286600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transcriptional heterogeneity due to plasticity of the epigenetic state of chromatin contributes to tumour evolution, metastasis and drug resistance^(1-3). However, the mechanisms that cause this epigenetic variation are incompletely understood. Here we identify micronuclei and chromosome bridges, aberrations in the nucleus common in cancer^(4,5), as sources of heritable transcriptional suppression. Using a combination of approaches, including long-term live-cell imaging and same-cell...]]></summary>
        <author>
            <name>Stamatis Papathanasiou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin]]></title>
        <id>pubmed:37286599</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286599/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumours most often arise from progression of precursor clones within a single anatomical niche. In the bone marrow, clonal progenitors can undergo malignant transformation to acute leukaemia, or differentiate into immune cells that contribute to disease pathology in peripheral tissues^(1-4). Outside the marrow, these clones are potentially exposed to a variety of tissue-specific mutational processes, although the consequences of this are unclear. Here we investigate the development of blastic...]]></summary>
        <author>
            <name>Gabriel K Griffin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[gUMI-BEAR, a modular, unsupervised population barcoding method to track variants and evolution at high resolution]]></title>
        <id>pubmed:37285353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage tracking provides a means to observe population makeup at the clonal level, allowing exploration of heterogeneity, evolutionary and developmental processes and individual clones' relative fitness. It has thus contributed significantly to understanding microbial evolution, organ differentiation and cancer heterogeneity, among others. Its use, however, is limited because existing methods are highly specific, expensive, labour-intensive, and, critically, do not allow the repetition...]]></summary>
        <author>
            <name>Shahar Rezenman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins]]></title>
        <id>pubmed:37285266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remain unclear. We conduct whole-exome and multiregional sequencing on 101 samples from 33 patients to elucidate their evolutionary paths. We identify four significantly mutated genes, TP53, RB1, APC, and CTNNB1. MANEC resembles chromosomal instability stomach...]]></summary>
        <author>
            <name>Miao-Zhen Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Heritable transcriptional defects from aberrations of nuclear architecture]]></title>
        <id>pubmed:37286600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transcriptional heterogeneity due to plasticity of the epigenetic state of chromatin contributes to tumour evolution, metastasis and drug resistance^(1-3). However, the mechanisms that cause this epigenetic variation are incompletely understood. Here we identify micronuclei and chromosome bridges, aberrations in the nucleus common in cancer^(4,5), as sources of heritable transcriptional suppression. Using a combination of approaches, including long-term live-cell imaging and same-cell...]]></summary>
        <author>
            <name>Stamatis Papathanasiou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin]]></title>
        <id>pubmed:37286599</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286599/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumours most often arise from progression of precursor clones within a single anatomical niche. In the bone marrow, clonal progenitors can undergo malignant transformation to acute leukaemia, or differentiate into immune cells that contribute to disease pathology in peripheral tissues^(1-4). Outside the marrow, these clones are potentially exposed to a variety of tissue-specific mutational processes, although the consequences of this are unclear. Here we investigate the development of blastic...]]></summary>
        <author>
            <name>Gabriel K Griffin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[gUMI-BEAR, a modular, unsupervised population barcoding method to track variants and evolution at high resolution]]></title>
        <id>pubmed:37285353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage tracking provides a means to observe population makeup at the clonal level, allowing exploration of heterogeneity, evolutionary and developmental processes and individual clones' relative fitness. It has thus contributed significantly to understanding microbial evolution, organ differentiation and cancer heterogeneity, among others. Its use, however, is limited because existing methods are highly specific, expensive, labour-intensive, and, critically, do not allow the repetition...]]></summary>
        <author>
            <name>Shahar Rezenman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins]]></title>
        <id>pubmed:37285266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remain unclear. We conduct whole-exome and multiregional sequencing on 101 samples from 33 patients to elucidate their evolutionary paths. We identify four significantly mutated genes, TP53, RB1, APC, and CTNNB1. MANEC resembles chromosomal instability stomach...]]></summary>
        <author>
            <name>Miao-Zhen Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Heritable transcriptional defects from aberrations of nuclear architecture]]></title>
        <id>pubmed:37286600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transcriptional heterogeneity due to plasticity of the epigenetic state of chromatin contributes to tumour evolution, metastasis and drug resistance^(1-3). However, the mechanisms that cause this epigenetic variation are incompletely understood. Here we identify micronuclei and chromosome bridges, aberrations in the nucleus common in cancer^(4,5), as sources of heritable transcriptional suppression. Using a combination of approaches, including long-term live-cell imaging and same-cell...]]></summary>
        <author>
            <name>Stamatis Papathanasiou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin]]></title>
        <id>pubmed:37286599</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286599/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumours most often arise from progression of precursor clones within a single anatomical niche. In the bone marrow, clonal progenitors can undergo malignant transformation to acute leukaemia, or differentiate into immune cells that contribute to disease pathology in peripheral tissues^(1-4). Outside the marrow, these clones are potentially exposed to a variety of tissue-specific mutational processes, although the consequences of this are unclear. Here we investigate the development of blastic...]]></summary>
        <author>
            <name>Gabriel K Griffin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[gUMI-BEAR, a modular, unsupervised population barcoding method to track variants and evolution at high resolution]]></title>
        <id>pubmed:37285353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage tracking provides a means to observe population makeup at the clonal level, allowing exploration of heterogeneity, evolutionary and developmental processes and individual clones' relative fitness. It has thus contributed significantly to understanding microbial evolution, organ differentiation and cancer heterogeneity, among others. Its use, however, is limited because existing methods are highly specific, expensive, labour-intensive, and, critically, do not allow the repetition...]]></summary>
        <author>
            <name>Shahar Rezenman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins]]></title>
        <id>pubmed:37285266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remain unclear. We conduct whole-exome and multiregional sequencing on 101 samples from 33 patients to elucidate their evolutionary paths. We identify four significantly mutated genes, TP53, RB1, APC, and CTNNB1. MANEC resembles chromosomal instability stomach...]]></summary>
        <author>
            <name>Miao-Zhen Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Heritable transcriptional defects from aberrations of nuclear architecture]]></title>
        <id>pubmed:37286600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transcriptional heterogeneity due to plasticity of the epigenetic state of chromatin contributes to tumour evolution, metastasis and drug resistance^(1-3). However, the mechanisms that cause this epigenetic variation are incompletely understood. Here we identify micronuclei and chromosome bridges, aberrations in the nucleus common in cancer^(4,5), as sources of heritable transcriptional suppression. Using a combination of approaches, including long-term live-cell imaging and same-cell...]]></summary>
        <author>
            <name>Stamatis Papathanasiou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin]]></title>
        <id>pubmed:37286599</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286599/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumours most often arise from progression of precursor clones within a single anatomical niche. In the bone marrow, clonal progenitors can undergo malignant transformation to acute leukaemia, or differentiate into immune cells that contribute to disease pathology in peripheral tissues^(1-4). Outside the marrow, these clones are potentially exposed to a variety of tissue-specific mutational processes, although the consequences of this are unclear. Here we investigate the development of blastic...]]></summary>
        <author>
            <name>Gabriel K Griffin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[gUMI-BEAR, a modular, unsupervised population barcoding method to track variants and evolution at high resolution]]></title>
        <id>pubmed:37285353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage tracking provides a means to observe population makeup at the clonal level, allowing exploration of heterogeneity, evolutionary and developmental processes and individual clones' relative fitness. It has thus contributed significantly to understanding microbial evolution, organ differentiation and cancer heterogeneity, among others. Its use, however, is limited because existing methods are highly specific, expensive, labour-intensive, and, critically, do not allow the repetition...]]></summary>
        <author>
            <name>Shahar Rezenman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins]]></title>
        <id>pubmed:37285266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remain unclear. We conduct whole-exome and multiregional sequencing on 101 samples from 33 patients to elucidate their evolutionary paths. We identify four significantly mutated genes, TP53, RB1, APC, and CTNNB1. MANEC resembles chromosomal instability stomach...]]></summary>
        <author>
            <name>Miao-Zhen Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Heritable transcriptional defects from aberrations of nuclear architecture]]></title>
        <id>pubmed:37286600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transcriptional heterogeneity due to plasticity of the epigenetic state of chromatin contributes to tumour evolution, metastasis and drug resistance^(1-3). However, the mechanisms that cause this epigenetic variation are incompletely understood. Here we identify micronuclei and chromosome bridges, aberrations in the nucleus common in cancer^(4,5), as sources of heritable transcriptional suppression. Using a combination of approaches, including long-term live-cell imaging and same-cell...]]></summary>
        <author>
            <name>Stamatis Papathanasiou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin]]></title>
        <id>pubmed:37286599</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286599/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumours most often arise from progression of precursor clones within a single anatomical niche. In the bone marrow, clonal progenitors can undergo malignant transformation to acute leukaemia, or differentiate into immune cells that contribute to disease pathology in peripheral tissues^(1-4). Outside the marrow, these clones are potentially exposed to a variety of tissue-specific mutational processes, although the consequences of this are unclear. Here we investigate the development of blastic...]]></summary>
        <author>
            <name>Gabriel K Griffin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[gUMI-BEAR, a modular, unsupervised population barcoding method to track variants and evolution at high resolution]]></title>
        <id>pubmed:37285353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage tracking provides a means to observe population makeup at the clonal level, allowing exploration of heterogeneity, evolutionary and developmental processes and individual clones' relative fitness. It has thus contributed significantly to understanding microbial evolution, organ differentiation and cancer heterogeneity, among others. Its use, however, is limited because existing methods are highly specific, expensive, labour-intensive, and, critically, do not allow the repetition...]]></summary>
        <author>
            <name>Shahar Rezenman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins]]></title>
        <id>pubmed:37285266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remain unclear. We conduct whole-exome and multiregional sequencing on 101 samples from 33 patients to elucidate their evolutionary paths. We identify four significantly mutated genes, TP53, RB1, APC, and CTNNB1. MANEC resembles chromosomal instability stomach...]]></summary>
        <author>
            <name>Miao-Zhen Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Heritable transcriptional defects from aberrations of nuclear architecture]]></title>
        <id>pubmed:37286600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transcriptional heterogeneity due to plasticity of the epigenetic state of chromatin contributes to tumour evolution, metastasis and drug resistance^(1-3). However, the mechanisms that cause this epigenetic variation are incompletely understood. Here we identify micronuclei and chromosome bridges, aberrations in the nucleus common in cancer^(4,5), as sources of heritable transcriptional suppression. Using a combination of approaches, including long-term live-cell imaging and same-cell...]]></summary>
        <author>
            <name>Stamatis Papathanasiou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin]]></title>
        <id>pubmed:37286599</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286599/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumours most often arise from progression of precursor clones within a single anatomical niche. In the bone marrow, clonal progenitors can undergo malignant transformation to acute leukaemia, or differentiate into immune cells that contribute to disease pathology in peripheral tissues^(1-4). Outside the marrow, these clones are potentially exposed to a variety of tissue-specific mutational processes, although the consequences of this are unclear. Here we investigate the development of blastic...]]></summary>
        <author>
            <name>Gabriel K Griffin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[gUMI-BEAR, a modular, unsupervised population barcoding method to track variants and evolution at high resolution]]></title>
        <id>pubmed:37285353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage tracking provides a means to observe population makeup at the clonal level, allowing exploration of heterogeneity, evolutionary and developmental processes and individual clones' relative fitness. It has thus contributed significantly to understanding microbial evolution, organ differentiation and cancer heterogeneity, among others. Its use, however, is limited because existing methods are highly specific, expensive, labour-intensive, and, critically, do not allow the repetition...]]></summary>
        <author>
            <name>Shahar Rezenman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins]]></title>
        <id>pubmed:37285266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remain unclear. We conduct whole-exome and multiregional sequencing on 101 samples from 33 patients to elucidate their evolutionary paths. We identify four significantly mutated genes, TP53, RB1, APC, and CTNNB1. MANEC resembles chromosomal instability stomach...]]></summary>
        <author>
            <name>Miao-Zhen Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Heritable transcriptional defects from aberrations of nuclear architecture]]></title>
        <id>pubmed:37286600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transcriptional heterogeneity due to plasticity of the epigenetic state of chromatin contributes to tumour evolution, metastasis and drug resistance^(1-3). However, the mechanisms that cause this epigenetic variation are incompletely understood. Here we identify micronuclei and chromosome bridges, aberrations in the nucleus common in cancer^(4,5), as sources of heritable transcriptional suppression. Using a combination of approaches, including long-term live-cell imaging and same-cell...]]></summary>
        <author>
            <name>Stamatis Papathanasiou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin]]></title>
        <id>pubmed:37286599</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286599/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumours most often arise from progression of precursor clones within a single anatomical niche. In the bone marrow, clonal progenitors can undergo malignant transformation to acute leukaemia, or differentiate into immune cells that contribute to disease pathology in peripheral tissues^(1-4). Outside the marrow, these clones are potentially exposed to a variety of tissue-specific mutational processes, although the consequences of this are unclear. Here we investigate the development of blastic...]]></summary>
        <author>
            <name>Gabriel K Griffin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[gUMI-BEAR, a modular, unsupervised population barcoding method to track variants and evolution at high resolution]]></title>
        <id>pubmed:37285353</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285353/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage tracking provides a means to observe population makeup at the clonal level, allowing exploration of heterogeneity, evolutionary and developmental processes and individual clones' relative fitness. It has thus contributed significantly to understanding microbial evolution, organ differentiation and cancer heterogeneity, among others. Its use, however, is limited because existing methods are highly specific, expensive, labour-intensive, and, critically, do not allow the repetition...]]></summary>
        <author>
            <name>Shahar Rezenman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins]]></title>
        <id>pubmed:37285266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remain unclear. We conduct whole-exome and multiregional sequencing on 101 samples from 33 patients to elucidate their evolutionary paths. We identify four significantly mutated genes, TP53, RB1, APC, and CTNNB1. MANEC resembles chromosomal instability stomach...]]></summary>
        <author>
            <name>Miao-Zhen Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Heritable transcriptional defects from aberrations of nuclear architecture]]></title>
        <id>pubmed:37286600</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286600/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transcriptional heterogeneity due to plasticity of the epigenetic state of chromatin contributes to tumour evolution, metastasis and drug resistance^(1-3). However, the mechanisms that cause this epigenetic variation are incompletely understood. Here we identify micronuclei and chromosome bridges, aberrations in the nucleus common in cancer^(4,5), as sources of heritable transcriptional suppression. Using a combination of approaches, including long-term live-cell imaging and same-cell...]]></summary>
        <author>
            <name>Stamatis Papathanasiou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ultraviolet radiation shapes dendritic cell leukaemia transformation in the skin]]></title>
        <id>pubmed:37286599</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37286599/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumours most often arise from progression of precursor clones within a single anatomical niche. In the bone marrow, clonal progenitors can undergo malignant transformation to acute leukaemia, or differentiate into immune cells that contribute to disease pathology in peripheral tissues^(1-4). Outside the marrow, these clones are potentially exposed to a variety of tissue-specific mutational processes, although the consequences of this are unclear. Here we investigate the development of blastic...]]></summary>
        <author>
            <name>Gabriel K Griffin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins]]></title>
        <id>pubmed:37285266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remain unclear. We conduct whole-exome and multiregional sequencing on 101 samples from 33 patients to elucidate their evolutionary paths. We identify four significantly mutated genes, TP53, RB1, APC, and CTNNB1. MANEC resembles chromosomal instability stomach...]]></summary>
        <author>
            <name>Miao-Zhen Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins]]></title>
        <id>pubmed:37285266</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37285266/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remain unclear. We conduct whole-exome and multiregional sequencing on 101 samples from 33 patients to elucidate their evolutionary paths. We identify four significantly mutated genes, TP53, RB1, APC, and CTNNB1. MANEC resembles chromosomal instability stomach...]]></summary>
        <author>
            <name>Miao-Zhen Qiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular evolution in different subtypes of multifocal hepatocellular carcinoma]]></title>
        <id>pubmed:37273168</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37273168/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our study comprehensively characterized the varied tumor clonal evolutionary history underlying different subtypes of MF-HCC and provided important implications for optimizing personalized clinical management for MF-HCC.]]></summary>
        <author>
            <name>Xia Tang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical significance of clonal evolution in chronic myeloid leukemia]]></title>
        <id>pubmed:37271527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37271527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the Philadelphia (Ph) chromosome, which is formed by a t (9;22)(q34;q11) translocation. The aberrant activation of the ABL1 tyrosine kinase is caused by the BCR::ABL1 fusion gene on the Ph chromosome, leading to significant leukemic cell proliferation. CML is typically diagnosed in the chronic phase with few clinical symptoms and progresses to a blast crisis within years. CML acquires additional genetic abnormalities...]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical significance of clonal evolution in chronic myeloid leukemia]]></title>
        <id>pubmed:37271527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37271527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the Philadelphia (Ph) chromosome, which is formed by a t (9;22)(q34;q11) translocation. The aberrant activation of the ABL1 tyrosine kinase is caused by the BCR::ABL1 fusion gene on the Ph chromosome, leading to significant leukemic cell proliferation. CML is typically diagnosed in the chronic phase with few clinical symptoms and progresses to a blast crisis within years. CML acquires additional genetic abnormalities...]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical significance of clonal evolution in chronic myeloid leukemia]]></title>
        <id>pubmed:37271527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37271527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the Philadelphia (Ph) chromosome, which is formed by a t (9;22)(q34;q11) translocation. The aberrant activation of the ABL1 tyrosine kinase is caused by the BCR::ABL1 fusion gene on the Ph chromosome, leading to significant leukemic cell proliferation. CML is typically diagnosed in the chronic phase with few clinical symptoms and progresses to a blast crisis within years. CML acquires additional genetic abnormalities...]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical significance of clonal evolution in chronic myeloid leukemia]]></title>
        <id>pubmed:37271527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37271527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the Philadelphia (Ph) chromosome, which is formed by a t (9;22)(q34;q11) translocation. The aberrant activation of the ABL1 tyrosine kinase is caused by the BCR::ABL1 fusion gene on the Ph chromosome, leading to significant leukemic cell proliferation. CML is typically diagnosed in the chronic phase with few clinical symptoms and progresses to a blast crisis within years. CML acquires additional genetic abnormalities...]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical significance of clonal evolution in chronic myeloid leukemia]]></title>
        <id>pubmed:37271527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37271527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the Philadelphia (Ph) chromosome, which is formed by a t (9;22)(q34;q11) translocation. The aberrant activation of the ABL1 tyrosine kinase is caused by the BCR::ABL1 fusion gene on the Ph chromosome, leading to significant leukemic cell proliferation. CML is typically diagnosed in the chronic phase with few clinical symptoms and progresses to a blast crisis within years. CML acquires additional genetic abnormalities...]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical significance of clonal evolution in chronic myeloid leukemia]]></title>
        <id>pubmed:37271527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37271527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the Philadelphia (Ph) chromosome, which is formed by a t (9;22)(q34;q11) translocation. The aberrant activation of the ABL1 tyrosine kinase is caused by the BCR::ABL1 fusion gene on the Ph chromosome, leading to significant leukemic cell proliferation. CML is typically diagnosed in the chronic phase with few clinical symptoms and progresses to a blast crisis within years. CML acquires additional genetic abnormalities...]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical significance of clonal evolution in chronic myeloid leukemia]]></title>
        <id>pubmed:37271527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37271527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the Philadelphia (Ph) chromosome, which is formed by a t (9;22)(q34;q11) translocation. The aberrant activation of the ABL1 tyrosine kinase is caused by the BCR::ABL1 fusion gene on the Ph chromosome, leading to significant leukemic cell proliferation. CML is typically diagnosed in the chronic phase with few clinical symptoms and progresses to a blast crisis within years. CML acquires additional genetic abnormalities...]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical significance of clonal evolution in chronic myeloid leukemia]]></title>
        <id>pubmed:37271527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37271527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the Philadelphia (Ph) chromosome, which is formed by a t (9;22)(q34;q11) translocation. The aberrant activation of the ABL1 tyrosine kinase is caused by the BCR::ABL1 fusion gene on the Ph chromosome, leading to significant leukemic cell proliferation. CML is typically diagnosed in the chronic phase with few clinical symptoms and progresses to a blast crisis within years. CML acquires additional genetic abnormalities...]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical significance of clonal evolution in chronic myeloid leukemia]]></title>
        <id>pubmed:37271527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37271527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the Philadelphia (Ph) chromosome, which is formed by a t (9;22)(q34;q11) translocation. The aberrant activation of the ABL1 tyrosine kinase is caused by the BCR::ABL1 fusion gene on the Ph chromosome, leading to significant leukemic cell proliferation. CML is typically diagnosed in the chronic phase with few clinical symptoms and progresses to a blast crisis within years. CML acquires additional genetic abnormalities...]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical significance of clonal evolution in chronic myeloid leukemia]]></title>
        <id>pubmed:37271527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37271527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the Philadelphia (Ph) chromosome, which is formed by a t (9;22)(q34;q11) translocation. The aberrant activation of the ABL1 tyrosine kinase is caused by the BCR::ABL1 fusion gene on the Ph chromosome, leading to significant leukemic cell proliferation. CML is typically diagnosed in the chronic phase with few clinical symptoms and progresses to a blast crisis within years. CML acquires additional genetic abnormalities...]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical significance of clonal evolution in chronic myeloid leukemia]]></title>
        <id>pubmed:37271527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37271527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the Philadelphia (Ph) chromosome, which is formed by a t (9;22)(q34;q11) translocation. The aberrant activation of the ABL1 tyrosine kinase is caused by the BCR::ABL1 fusion gene on the Ph chromosome, leading to significant leukemic cell proliferation. CML is typically diagnosed in the chronic phase with few clinical symptoms and progresses to a blast crisis within years. CML acquires additional genetic abnormalities...]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical significance of clonal evolution in chronic myeloid leukemia]]></title>
        <id>pubmed:37271527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37271527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the Philadelphia (Ph) chromosome, which is formed by a t (9;22)(q34;q11) translocation. The aberrant activation of the ABL1 tyrosine kinase is caused by the BCR::ABL1 fusion gene on the Ph chromosome, leading to significant leukemic cell proliferation. CML is typically diagnosed in the chronic phase with few clinical symptoms and progresses to a blast crisis within years. CML acquires additional genetic abnormalities...]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical significance of clonal evolution in chronic myeloid leukemia]]></title>
        <id>pubmed:37271527</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37271527/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic myeloid leukemia (CML) is a hematological malignancy characterized by the Philadelphia (Ph) chromosome, which is formed by a t (9;22)(q34;q11) translocation. The aberrant activation of the ABL1 tyrosine kinase is caused by the BCR::ABL1 fusion gene on the Ph chromosome, leading to significant leukemic cell proliferation. CML is typically diagnosed in the chronic phase with few clinical symptoms and progresses to a blast crisis within years. CML acquires additional genetic abnormalities...]]></summary>
        <author>
            <name>Yotaro Ochi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230625211348&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils]]></title>
        <id>pubmed:37267914</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267914/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations commonly occur in hematopoietic stem cells (HSCs). Some mutant clones outgrow through clonal hematopoiesis (CH) and produce mutated immune progenies shaping host immunity. Individuals with CH are asymptomatic but have an increased risk of developing leukemia, cardiovascular and pulmonary inflammatory diseases, and severe infections. Using genetic engineering of human HSCs (hHSCs) and transplantation in immunodeficient mice, we describe how a commonly mutated gene in CH, TET2,...]]></summary>
        <author>
            <name>Hector Huerga Encabo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome- positive myelodysplastic syndrome with single lineage dysplasia]]></title>
        <id>pubmed:37267684</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37267684/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a group of acquired clonal disorders characterized by dysplastic and ineffective hematopoiesis in the bone marrow. Various specific karyotypic and molecular abnormalities associated with MDS further guide the prognosis. Although translocation t(9;22)(q34;q11) (Philadelphia positive [Ph+]) and corresponding BCR-ABL fusion transcript are classically defined to differentiate CML from non-CML myeloproliferative disorders, it is also associated with adult acute...]]></summary>
        <author>
            <name>Ajeet Kumar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact and outcomes of cancer-macrophage fusion]]></title>
        <id>pubmed:37264310</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37264310/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-06-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The study revealed that tumor-somatic cell fusion is a potent environmental modifier that can modulate tumor survival and evolution, despite its relatively low occurrence. These findings suggest that tumor-somatic cell fusion could be a promising target for developing new cancer therapies. Furthermore, this study provides an experimental animal platform to investigate cancer-myeloid fusion and highlights the potential role of tumor-somatic cell fusion in modulating the tumor...]]></summary>
        <author>
            <name>Mengtao Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230624211813&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230623211123&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The impact of prenatal inflammation on hematopoietic development]]></title>
        <id>pubmed:37254855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37254855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: Inflammation is now recognized as a major regulator of hematopoietic stem cell (HSC) function. Adult hematopoietic stem cells can adaptively modulate hematopoietic output in direct response to acute infection and inflammation. Conversely, prolonged exposure to inflammation can drive impaired HSC function, clonal expansion, and malignant transformation. As compared with adult hematopoiesis, the effects of prenatal inflammation on developing hematopoietic stem cells are...]]></summary>
        <author>
            <name>Nicole A Tseng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deterministic evolution and stringent selection during preneoplasia]]></title>
        <id>pubmed:37258665</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37258665/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The earliest events during human tumour initiation, although poorly characterized, may hold clues to malignancy detection and prevention¹. Here we model occult preneoplasia by biallelic inactivation of TP53, a common early event in gastric cancer, in human gastric organoids. Causal relationships between this initiating genetic lesion and resulting phenotypes were established using experimental evolution in multiple clonally derived cultures over 2 years. TP53 loss elicited progressive...]]></summary>
        <author>
            <name>Kasper Karlsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FIRRM/C1orf112 mediates resolution of homologous recombination intermediates in response to DNA interstrand crosslinks]]></title>
        <id>pubmed:37256941</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256941/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[DNA interstrand crosslinks (ICLs) pose a major obstacle for DNA replication and transcription if left unrepaired. The cellular response to ICLs requires the coordination of various DNA repair mechanisms. Homologous recombination (HR) intermediates generated in response to ICLs, require efficient and timely conversion by structure-selective endonucleases. Our knowledge on the precise coordination of this process remains incomplete. Here, we designed complementary genetic screens to map the...]]></summary>
        <author>
            <name>Abdelghani Mazouzi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic heterogeneity in p53-null leukemia increases transiently with spindle assembly checkpoint inhibition and is not rescued by p53]]></title>
        <id>pubmed:37256347</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37256347/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome gains or losses often lead to copy number variations (CNV) and loss of heterozygosity (LOH). Both quantities are low in hematologic "liquid" cancers versus solid tumors in data of The Cancer Genome Atlas (TCGA) that also shows the fraction of a genome affected by LOH is ~ one-half of that with CNV. Suspension cultures of p53-null THP-1 leukemia-derived cells conform to these trends, despite novel evidence here of genetic heterogeneity and transiently elevated CNV after perturbation....]]></summary>
        <author>
            <name>Mai Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230622211122&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia, and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia (AML) with...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Nore1 inhibits age-associated myeloid lineage skewing and clonal hematopoiesis, but facilitates termination of emergency (stress) granulopoiesis]]></title>
        <id>pubmed:37247756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37247756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Age-associated bone marrow changes include myeloid skewing and mutations that lead to clonal hematopoiesis. Molecular mechanisms for these events are ill-defined, but decreased expression of Irf8/Icsbp (interferon regulatory factor 8/interferon consensus sequence binding protein) in aging hematopoietic stem cells (HSCs) may contribute. Irf8 functions as a leukemia suppressor for chronic myeloid leukemia (CML), and young Irf8^(-/-) mice have neutrophilia with progression to acute myeloid leukemia...]]></summary>
        <author>
            <name>Olatundun Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Latest Findings on the Mechanism of the Interaction Between Multiple Myeloma Cells and Bone Marrow Microenvironment]]></title>
        <id>pubmed:37248571</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248571/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple myeloma (MM) is a hematologic malignancy of terminally differentiated plasma cells. The mechanisms of the pathogenesis and progression of MM include genetic abnormalities of the MM cells and the interaction between MM cells and bone marrow microenvironment (BMME). MM cells start malignant proliferation in BMME and contribute to the pathogenesis and progression of MM through direct or indirect interactions between cells and the extracellular matrix. Exploring the mechanism of interaction...]]></summary>
        <author>
            <name>Ni-Han He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical and translational relevance of intratumor heterogeneity]]></title>
        <id>pubmed:37248149</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37248149/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical...]]></summary>
        <author>
            <name>Marie-Anne Goyette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230621210458&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Association between genetically determined telomere length and health-related outcomes: A systematic review and meta-analysis of Mendelian randomization studies]]></title>
        <id>pubmed:37232505</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37232505/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging evidence has shown that leukocyte telomere length (LTL) is associated with various health-related outcomes, while the causality of these associations remains unclear. We performed a systematic review and meta-analysis of current evidence from Mendelian randomization (MR) studies on the association between LTL and health-related outcomes. We searched PubMed, Embase, and Web of Science up to April 2022 to identify eligible MR studies. We graded the evidence level of each MR association...]]></summary>
        <author>
            <name>Boran Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome]]></title>
        <id>pubmed:37237325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37237325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: In conclusion, hypermethylation of the LEP promoter is an early and frequent event in myeloid neoplasms and is associated with a worse prognosis.]]></summary>
        <author>
            <name>Katja Kaastrup</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230620210358&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230619210151&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Inflammasomes and Atherosclerosis: a Mixed Picture]]></title>
        <id>pubmed:37228237</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37228237/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) and colchicine trials suggest an important role of inflammasomes and their major product IL-1β (interleukin 1β) in human atherosclerotic cardiovascular disease. Moreover, studies in mouse models indicate a causal role of inflammasomes and IL-1β in atherosclerosis. However, recent studies have led to a more granular view of the role of inflammasomes in atherosclerosis. Studies in hyperlipidemic mouse models suggest that prominent...]]></summary>
        <author>
            <name>Alan R Tall</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230618210354&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230617211143&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Malignant clonal evolution from high proportion of monocytes in patients with aplastic anemia: a case report]]></title>
        <id>pubmed:37223330</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223330/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: The proportion of monocytes in the blood and bone marrow of AA patients should be closely monitored. Hematopoietic stem cell transplantation (HSCT) should be performed as early as possible once monocytes continue to increase or are associated with phenotypic abnormalities or genetic mutations. The unique value of this study is that although there were case reports about AA-derived acute leukemia, we suggested that an early high proportion of monocytes may predict malignant clonal...]]></summary>
        <author>
            <name>Qiuhao Fu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Synergistic inter-clonal cooperation involving crosstalk, co-option and co-dependency can enhance the invasiveness of genetically distant cancer clones]]></title>
        <id>pubmed:37226092</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37226092/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Based on our findings, we propose a model in which crosstalk, co-option, and co-dependency can facilitate the evolution of synergistic cooperative interactions between genetically distant clones. Specifically, we suggest that synergistic cooperative interactions can easily emerge, regardless of the degree of overall genetic/genealogical relatedness, via crosstalk involving metastatic clones able to constitutively secrete molecules that induce and maintain their own malignant state...]]></summary>
        <author>
            <name>Caroline S Carneiro</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis]]></title>
        <id>pubmed:37223675</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37223675/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Initial diagnosis of overt myeloproliferative neoplasms (MPNs) represents the juncture during clonal evolution when symptoms or complications prompt an afflicted individual to seek medical attention. In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (CALR) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). In the current study, we describe a healthy CALR mutated...]]></summary>
        <author>
            <name>Lasse Kjær</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230616210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer]]></title>
        <id>pubmed:37221411</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37221411/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE OF REVIEW: This review focuses on vascular complications associated with chronic myeloproliferative neoplasms (MPN) and more specifically aims to discuss the clinical and biological evidence supporting the existence of a link between clonal hematopoiesis, cardiovascular events (CVE), and solid cancer (SC).]]></summary>
        <author>
            <name>Tiziano Barbui</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes]]></title>
        <id>pubmed:37220750</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37220750/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Limited evidence exists on the impact of spatial and temporal heterogeneity of high-grade serous ovarian cancer (HGSOC) on tumor evolution, clinical outcomes, and surgical operability. We perform systematic multi-site tumor mapping at presentation and matched relapse from 49 high-tumor-burden patients, operated up front. From SNP array-derived copy-number data, we categorize dendrograms representing tumor clonal evolution as sympodial or dichotomous, noting most chemo-resistant patients favor...]]></summary>
        <author>
            <name>Paula Cunnea</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA]]></title>
        <id>pubmed:37217808</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37217808/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We characterized the genomic alterations during HCC vascular invasion and revealed a previously undescribed evolution pattern of ctDNA in HCC. A novel multiomics-based signature was developed to identify high-risk relapse populations.]]></summary>
        <author>
            <name>Chenhao Zhou</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An unusual ectopic thymoma clonal evolution analysis: A case report]]></title>
        <id>pubmed:37215501</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37215501/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Thymomas and thymic carcinomas are rare and primary tumors of the mediastinum which is derived from the thymic epithelium. Thymomas are the most common primary anterior mediastinal tumor, while ectopic thymomas are rarer. Mutational profiles of ectopic thymomas may help expand our understanding of the occurrence and treatment options of these tumors. In this report, we sought to elucidate the mutational profiles of two ectopic thymoma nodules to gain deeper understanding of the molecular genetic...]]></summary>
        <author>
            <name>Sijia Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Morphology of myeloproliferative neoplasms]]></title>
        <id>pubmed:37211431</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37211431/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease...]]></summary>
        <author>
            <name>Zi Yun Ng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma]]></title>
        <id>pubmed:37207655</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37207655/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian high-grade serous carcinoma (HGSC) is typically diagnosed at an advanced stage, with multiple genetically heterogeneous clones existing in the tumors long before therapeutic intervention. Herein we integrate clonal composition and topology using whole-genome sequencing data from 510 samples of 148 patients with HGSC in the prospective, longitudinal, multiregion DECIDER study. Our results reveal three evolutionary states, which have distinct features in genomics, pathways, and...]]></summary>
        <author>
            <name>Alexandra Lahtinen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma]]></title>
        <id>pubmed:37205910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...]]></summary>
        <author>
            <name>Rebecca L Murdaugh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230615210421&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230614210352&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230613210413&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230612210456&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230611210824&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230610211246&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230609210213&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230608210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease]]></title>
        <id>pubmed:37197843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.]]></summary>
        <author>
            <name>Esra D Gumuser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms]]></title>
        <id>pubmed:37195768</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...]]></summary>
        <author>
            <name>Zhuoer Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Epidemiology and Pathogenesis of Myelodysplastic Syndrome]]></title>
        <id>pubmed:37195766</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...]]></summary>
        <author>
            <name>Lara K Rotter</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study]]></title>
        <id>pubmed:37196833</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.]]></summary>
        <author>
            <name>Timothy Qi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms]]></title>
        <id>pubmed:37195777</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...]]></summary>
        <author>
            <name>Jessica M Stempel</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis]]></title>
        <id>pubmed:37194418</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...]]></summary>
        <author>
            <name>Sheehyun Kim</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230607210603&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230606210835&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230605210701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230604210531&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230603211539&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Stem cell regulation and dynamics in myeloid malignancies]]></title>
        <id>pubmed:37191835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...]]></summary>
        <author>
            <name>Goro Sashida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230527210351&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Toward a systems-level probing of tumor clonality]]></title>
        <id>pubmed:37192968</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...]]></summary>
        <author>
            <name>Emanuelle I Grody</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin]]></title>
        <id>pubmed:37192000</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...]]></summary>
        <author>
            <name>Jan Attig</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities]]></title>
        <id>pubmed:37186988</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...]]></summary>
        <author>
            <name>Ismail Elbaz Younes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230602210410&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230601210630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230531211907&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230530210538&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study]]></title>
        <id>pubmed:37175518</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...]]></summary>
        <author>
            <name>Dominik Kodada</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives]]></title>
        <id>pubmed:37173944</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...]]></summary>
        <author>
            <name>Olisaemeka Ogbue</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Utility of polygenic risk scores in UK cancer screening: a modelling analysis]]></title>
        <id>pubmed:37178708</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...]]></summary>
        <author>
            <name>Catherine Huntley</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer]]></title>
        <id>pubmed:37176124</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...]]></summary>
        <author>
            <name>Daeun Ryu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice]]></title>
        <id>pubmed:37172086</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...]]></summary>
        <author>
            <name>Wen Bu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230529210010&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230521210056&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity]]></title>
        <id>pubmed:37170152</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.]]></summary>
        <author>
            <name>Francesca Bersani</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival]]></title>
        <id>pubmed:37168490</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...]]></summary>
        <author>
            <name>Peter Bailey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop]]></title>
        <id>pubmed:37167533</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.]]></summary>
        <author>
            <name>Catalina Amador</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230528210011&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230527210349&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230526210002&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230525205746&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board]]></title>
        <id>pubmed:37159554</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.]]></summary>
        <author>
            <name>Camila B Xavier</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia]]></title>
        <id>pubmed:37160316</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...]]></summary>
        <author>
            <name>Siba El Hussein</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Reuniting philosophy and science to advance cancer research]]></title>
        <id>pubmed:37157910</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...]]></summary>
        <author>
            <name>Thomas Pradeu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230524205854&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study]]></title>
        <id>pubmed:37156299</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...]]></summary>
        <author>
            <name>Kaushik Amancherla</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma]]></title>
        <id>pubmed:37155154</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers originate from a single cell according to Nowell's theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...]]></summary>
        <author>
            <name>Weilong Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms]]></title>
        <id>pubmed:37153874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...]]></summary>
        <author>
            <name>Damien Luque Paz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis]]></title>
        <id>pubmed:37150255</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...]]></summary>
        <author>
            <name>Chao Cheng</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin]]></title>
        <id>pubmed:37149862</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...]]></summary>
        <author>
            <name>Claudia Garcia-Diaz</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230523205858&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230522205732&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230521210055&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230520210114&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230519205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230518205810&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population]]></title>
        <id>pubmed:37146604</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...]]></summary>
        <author>
            <name>Isabelle A van Zeventer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells]]></title>
        <id>pubmed:37146586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...]]></summary>
        <author>
            <name>Sven Turkalj</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples]]></title>
        <id>pubmed:37146250</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...]]></summary>
        <author>
            <name>Jasneet Kaur Khalsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications]]></title>
        <id>pubmed:37143651</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...]]></summary>
        <author>
            <name>Franziska Darzentas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230517205652&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Familial Clonal Hematopoiesis in a Long Telomere Syndrome]]></title>
        <id>pubmed:37140166</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).]]></summary>
        <author>
            <name>Emily A DeBoy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230515205818&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution]]></title>
        <id>pubmed:37140929</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.]]></summary>
        <author>
            <name>Bahar Rastegar</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms]]></title>
        <id>pubmed:37139709</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...]]></summary>
        <author>
            <name>Anna Hinze</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer]]></title>
        <id>pubmed:37133448</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...]]></summary>
        <author>
            <name>Niccolo Roda</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma]]></title>
        <id>pubmed:37131267</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.]]></summary>
        <author>
            <name>Jiayu Liang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The genetic determinants of recurrent somatic mutations in 43,693 blood genomes]]></title>
        <id>pubmed:37126548</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-05-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...]]></summary>
        <author>
            <name>Joshua S Weinstock</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Mitigating age-related somatic mutation burden]]></title>
        <id>pubmed:37121869</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...]]></summary>
        <author>
            <name>Jan Vijg</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230516205931&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230515205819&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230514205932&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230513210018&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230512205523&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230511205726&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230510205718&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230509205648&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230508205817&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230507205525&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230506210046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230505205328&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230504205311&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230503205635&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230502205757&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230501205822&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230430210026&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[VEXAS: is it time to reshape the nosology of clonal hematopoiesis?]]></title>
        <id>pubmed:37119011</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230429210234&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-04-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: The recent description of VEXAS (for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) challenges the nosological framework of myelodysplastic syndromes.]]></summary>
        <author>
            <name>Pierre Sujobert</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nodal interferon exposure drives tumour-specific tolerance]]></title>
        <id>72a3a11d39c217b1a80cbb551444e6f6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1533878403463405569"/>
        <updated>2022-06-06T18:28:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nodal interferon exposure drives tumour-specific tolerance https://t.co/FT4NeBcFTg pic.twitter.com/NRHkVDUsOr
— NatureReviewsCancer (@NatureRevCancer) June 6, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VIBConferences: #Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.⏰Registration Deadline: Thursday 2 June. Read more]]></title>
        <id>bb6bc242bcbc356c4a38db850e74d812</id>
        <link href="https://twitter.com/VIBConferences/status/1531132720952266752"/>
        <updated>2022-05-30T04:37:42.000Z</updated>
        <summary type="html"><![CDATA[#Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.
⏰Registration Deadline: Thursday 2 June. Read more https://t.co/cc0HC5cj6W pic.twitter.com/u8LFuzBbsV
— VIB Conferences (@VIBConferences) May 30, 2022]]></summary>
        <author>
            <name>@VIBConferences</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy]]></title>
        <id>ed6c996dc1a718afb523de6229a53131</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530198403686072320"/>
        <updated>2022-05-27T14:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy https://t.co/wjuHplkpof pic.twitter.com/1SoKYhRsPO
— NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content 👇🏻💌]]></title>
        <id>d15a3a4b24853812d7fa21fd56de5815</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530174481313972224"/>
        <updated>2022-05-27T13:10:00.000Z</updated>
        <summary type="html"><![CDATA[Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content 👇🏻
💌 https://t.co/Fo6XRWV3OZ@natrescancer pic.twitter.com/rbxRPqLV6g
— NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@UlrikeHarjes: This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer:  do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest☺️]]></title>
        <id>fe13755a2693ea65459e5e21df097d2a</id>
        <link href="https://twitter.com/UlrikeHarjes/status/1529747629936193537"/>
        <updated>2022-05-26T08:53:50.000Z</updated>
        <summary type="html"><![CDATA[This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer: https://t.co/p3Y2cdNhco
I do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest☺️ https://t.co/qWH2dTv8j9
— Ulrike Harjes (@UlrikeHarjes) May 26, 2022]]></summary>
        <author>
            <name>@UlrikeHarjes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Developing dietary interventions as therapy for cancer]]></title>
        <id>9ba5279424b31b0122a4ae20c18e6d03</id>
        <link href="https://twitter.com/NatureRevCancer/status/1529516411059437568"/>
        <updated>2022-05-25T17:35:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Developing dietary interventions as therapy for cancer https://t.co/ijuqctk1wJ pic.twitter.com/KHPpMKnCFa
— NatureReviewsCancer (@NatureRevCancer) May 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Digging for treasures in the tumour interactome]]></title>
        <id>611d40f2e6ea2796b028bebda41a86dd</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526928478490095616"/>
        <updated>2022-05-18T14:11:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Digging for treasures in the tumour interactome https://t.co/NhHYAwUgLE
— NatureReviewsCancer (@NatureRevCancer) May 18, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: As part of our overall commitment to diversity, equity and inclusion at Springer Nature, we’d like to better understand what DEI means within the global research community. Take the survey here]]></title>
        <id>9590a971b00448cd312078183965b21d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526560254091313156"/>
        <updated>2022-05-17T13:48:21.000Z</updated>
        <summary type="html"><![CDATA[As part of our overall commitment to diversity, equity and inclusion at Springer Nature, we’d like to better understand what DEI means within the global research community. Take the survey here https://t.co/03yLiUxFTq
— NatureReviewsCancer (@NatureRevCancer) May 17, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT 🧰 🛠️ where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial 👇🏻]]></title>
        <id>aa38ff4245b93e964773f191844ddc7a</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524772831904509953"/>
        <updated>2022-05-12T15:25:46.000Z</updated>
        <summary type="html"><![CDATA[Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT 🧰 🛠️ where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial 👇🏻 https://t.co/VbyoUJmTRJ
— NatureReviewsCancer (@NatureRevCancer) May 12, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tools for the next generation]]></title>
        <id>65aca76b9f794aaa668d84ad32dca4a0</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524068259712036864"/>
        <updated>2022-05-10T16:46:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tools for the next generation https://t.co/lEzTPFYDf5
— NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon]]></title>
        <id>afa9b6784b4ccc7c05ed4efd26ddfb2d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524022709386190856"/>
        <updated>2022-05-10T13:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon https://t.co/XXT0c9SAYX
— NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VarunVenkatara2: Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter]]></title>
        <id>43e2d5ccebc9030f737d656f47ac9d98</id>
        <link href="https://twitter.com/VarunVenkatara2/status/1520050291986604033"/>
        <updated>2022-04-29T14:40:05.000Z</updated>
        <summary type="html"><![CDATA[Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter https://t.co/S55cKTGNFd
— Varun Venkataramani (@VarunVenkatara2) April 29, 2022]]></summary>
        <author>
            <name>@VarunVenkatara2</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! An inhospitable site]]></title>
        <id>9f6b8644378881f4c2e6b6833c93fc2f</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020349068316673"/>
        <updated>2022-04-29T12:41:06.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! An inhospitable site https://t.co/0dvqIKCWxh pic.twitter.com/PtY8J9Fz7r
— NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Disconnecting multicellular networks in brain tumours]]></title>
        <id>f6d91efcd60dae769e2722585bdfa8df</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020340201598978"/>
        <updated>2022-04-29T12:41:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Disconnecting multicellular networks in brain tumours https://t.co/LJrzy8bRma pic.twitter.com/CO7BnooP0r
— NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.💌]]></title>
        <id>76e3b436bc8e43ad21366a80c120e395</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519678964364623872"/>
        <updated>2022-04-28T14:04:34.000Z</updated>
        <summary type="html"><![CDATA[Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.
💌 https://t.co/vQwHFJhpwv@natrescancer pic.twitter.com/6kYgjRYhdT
— NatureReviewsCancer (@NatureRevCancer) April 28, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@tmurraystewart: Our latest publication on #polyamines is online!@HopkinsMedicine]]></title>
        <id>fdf224ea293cdf039086d16e5699a59a</id>
        <link href="https://twitter.com/tmurraystewart/status/1519413460978704384"/>
        <updated>2022-04-27T20:29:33.000Z</updated>
        <summary type="html"><![CDATA[Our latest publication on #polyamines is online!@HopkinsMedicine https://t.co/ehRGgN1w9R
— Tracy Murray Stewart (@tmurraystewart) April 27, 2022]]></summary>
        <author>
            <name>@tmurraystewart</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity]]></title>
        <id>4f43226ec4dc8e531ff6e64a9c5ab8e6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519381375874265088"/>
        <updated>2022-04-27T18:22:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity https://t.co/YCJX1hRQLO pic.twitter.com/zRUCRNXyxH
— NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.📯]]></title>
        <id>a44ed79b9f76aad377b9272fb392f553</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519317944995569664"/>
        <updated>2022-04-27T14:10:00.000Z</updated>
        <summary type="html"><![CDATA[NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.
📯 https://t.co/JTUhX0DHQ1@natrescancer pic.twitter.com/2PdCmsDu2p
— NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino  @natrescancer @Columbia]]></title>
        <id>06ff7641d8f5fcc0dff91f835ac3bbc1</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518967636561956865"/>
        <updated>2022-04-26T14:58:00.000Z</updated>
        <summary type="html"><![CDATA[In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino
 https://t.co/GeTVCMJQsp @natrescancer
 @Columbia pic.twitter.com/ZXW6A0Fe0c
— NatureReviewsCancer (@NatureRevCancer) April 26, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tracking dormant disseminated tumour cells]]></title>
        <id>96b2ddff4eb269cf343213c6a1b1ce95</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518563607440621569"/>
        <updated>2022-04-25T12:12:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tracking dormant disseminated tumour cells https://t.co/kSXyWAvCxF
— NatureReviewsCancer (@NatureRevCancer) April 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
</feed>